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Preface 
 
 
This research report is of a cost of illness study of multiple sclerosis in the Canterbury / 
Westland region.  It outlines the economic costs of relapsing-remitting multiple sclerosis to the 
people with the condition, those that support these people and the government.  A summary of 
such costs has not been established in New Zealand before now.  The findings in this report will 
be of interest to all people affected by multiple sclerosis, regional and national health funding 
agencies, and health and other social policy analysts in New Zealand.   
 
A member of the AERU assisted the Multiple Sclerosis and Parkinsons Society of Canterbury 
Inc. in conducting this study.  The main research work was undertaken independently by the 
Society.  The AERU has agreed to further assist by publishing the report as an AERU Research 
Report. 
 
Ross Cullen 
Director 
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Summary 
 
 
Conclusions: 
• Cost findings here are conservative due to the limited research sub-population, that is, 
people with relapsing-remitting multiple sclerosis (RRMS) matching diagnostic criteria 
from 1984 to 1995 inclusive, and unrecorded indirect costs.  An in-depth national study 
across all levels of MS would show higher costs, which would be comparable to other 
international studies. 
• Costs are higher for people that have had RRMS for a shorter time (0-9 years), however 
people with RRMS longer (10+ years) cost the government more. 
• The use of alternative treatments among people with MS appears to be high. Research on 
the frequency of alternative use, and rationale of people in choosing these options, is 
warranted. 
• There may be an incentive for those in policy making regarding funding treatments to 
target MS at an earlier stage in an attempt to reduce morbidity and delay disability.  The 
aim would be to encourage financial independence, therefore reducing longer-term 
government costs. 
 
Background and Rationale: 
• Various international studies have been conducted on the costs of MS at national levels. 
• There is no information about the economic costs of MS in New Zealand. 
 
Research Objectives: 
• A main objective was to measure costs of RRMS within the Canterbury / Westland 
region. 
• The key research questions were what are the economic costs of RRMS, and in what way 
do costs change over time? 
 
Methods: 
• This was a cost of illness study using a prevalence approach, and bottom-up method.  
The information was gathered using structured questionnaires in one-to-one interviews. 
• Seventy-three people fitting diagnostic criteria for relapsing-remitting multiple sclerosis 
were identified as the target population, from which 59 were interviewed. 
• Two diagnostic groups were established for cost over time analysis. They were Group 1 
(24 respondents diagnosed from 1984 to 1989, inclusive) and Group 2 (35 respondents 
diagnosed from 1990 to 1995, inclusive). 
 
Results: 
• The total cost of MS to the 59 research respondents for 1999 was $1,171,593.  The mean 
annual cost of MS per person was $19,857. 
• Direct costs were 50.5 per cent and indirect costs were 49.5 per cent of all costs. 
• Government paid about one third (35 per cent) of all costs associated with MS and just 
over one in five respondents (22 per cent) did not receive any form of government 
assistance. 
• The highest cost category was Income and Employment Costs (loss of earnings) with 53 
per cent of all costs.  Second highest was Resource Costs at 31 per cent.  
• The three highest separate costs were: 1. Potential annual income lost; 2. Benefit 
assistance; and, 3. Family informal assistance.  Only benefit assistance was a direct cost. 
• The three most commonly incurred costs were: 1. Transport costs; 2. GP costs; and, 3. 
Personal resource costs.  The six most common costs were paid for by people with MS. 
 xii
• On average, people who have had RRMS for longer cost the government more (i.e. 
transfers) and require more personal assistance than people who have had MS for a 
shorter time. 
• On average, people with RRMS for the shorter time incurred greater: medical expenses; 
personal expense for resources, services and other costs; and loss of potential income.  
Overall, they paid more MS related costs themselves, had proportionally less assistance 
from government and had the greater total of MS related costs. 
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Chapter 1  
Introduction: Background, Objectives and Methods 
 
 
1.1  Introduction 
 
There have been economic assessments of the costs of multiple sclerosis (MS) undertaken in a 
number of different countries.  The “cost of illness” studies have used different methods, with 
varying results, to determine economic costs associated with MS.  A common consensus in the 
different analyses is that the economic costs are shared between those with the condition, close 
friends and family, the State and the community in which people with MS live.  The proportional 
differences between those who share the costs within society depend on the levels of community 
and State assistance that exist for social services, particularly health, housing and employment.  
New Zealand has a similar assistance structure to many other countries, however a study of the 
cost of MS had not occurred in New Zealand to date.   
 
People with MS will not only incur the real costs associated with managing the illness, but also 
the costs associated with the changes they make in their lifestyles.  This report examines the cost 
of an MS sub-population in the Canterbury/Westland region of New Zealand, and determines the 
proportions of economic costs for this condition borne by this country’s central government and 
the people with MS. 
 
 
1.2 Background 
 
The literature on MS reports the social and psychological impacts of the disease, and 
assessments of economic cost.  Research often uses any one of a number of scales for the 
assessment of the extent of MS. 
 
Research on economic costs of MS has established that they are high but the estimates are quite 
variable.  Inman (1984) has addressed the important issue of assessing economic costs associated 
with each stage of disability as measured by a mobility index.  Results showed that United States 
families face annual medical costs plus annual loss of earnings of as much as US$15,000, per 
family, and individual lifetime costs may be as high as US$151,000.  Inman goes on to calculate 
the current and future costs to society of MS and to consider optimum insurance design.  
Bourdette et al. (1993) found in a retrospective study of 165 MS patients that total health care 
costs averaged US$35,000 per annum, and that total costs correlated with the scores on the 
Expanded Disability Status Scale (EDSS) and the Incapacity Status Scale (ISS), (r = 0.61 and 
0.64 respectively).  They also found that over three years there were 40 hospitalisations, which 
may have been preventable with outpatient management that had a total cost of US$412,800.  
Todd (1995) cites research by Brown that showed that Canadian average healthcare costs for MS 
patients were $4,000 per person in 1993 versus $1,600 per person in the Nova Scotian 
population.  MS patient treatment costs increased with patient age.  Research by Holmes et al. 
(1995) sampled members of the UK MS Society to estimate that the total annual cost burden was 
1.2 billion sterling.  Whetten-Goldstein et al. (1996) estimated that the annual cost of MS for a 
random sample of 606 sufferers and their households in the United States was nearly 
US$35,000.  The estimated annual cost for chronic progressive MS was US$50,000.  Costs 
included personal services, alterations to home and vehicle, purchase of special equipment and 
lost earnings. 
 
Lissovoy and Lazarus (1994) outline the rationale and methods used in ‘cost of illness’ analysis 
noting that there are two approaches.  First, the human capital approach measures the burden of 
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illness in terms of direct and indirect costs.  Direct costs include diagnosis, treatment, 
medication, rehabilitation, transportation to obtain care, special equipment and alterations to 
property.  Other direct costs include aggregate costs such as the cost of medical research, 
professional training, clinical facilities and health administration1.  Indirect costs include lost 
earnings, the estimated market value of home help and workplace effects (e.g. reduction in work 
effectiveness and reduced opportunities for promotion). Previous studies tend to concentrate on 
hospitalisation, outpatient care and drug treatment.  Indirect costs relate to the loss of production 
due to short-term illness, disability or premature death.  Also included is the loss of productivity 
for family members. Second, the willingness-to-pay approach measures the amount a group of 
individuals is prepared to pay to reduce their risk of incurring or dying from a disease.  This 
approach is not considered in the present research because the human capital approach can be 
applied to MS patients effectively.  
 
 
1.3  Research Objectives 
 
The aim of this research was to estimate the costs associated with patients who have MS, 
including costs related to exacerbations and costs that derive from the consequences of MS.  The 
research hypothesis was that: 
 
1. The economic costs of MS are high. 
2. The economic costs of MS are positively correlated to time with MS. 
 
It was expected that if duration with MS lead to increased frequency of relapses or the 
development of long-term disability then it was likely that both personal and societal costs 
incurred in managing or treating the disease would also increase.  The key questions then 
became: what is the economic cost of MS, and in what way do costs change over time? 
 
The main objective of the research was to measure the economic cost of MS within the 
Canterbury region.  The specific research objectives were: 
 
1. To use the resources of the Multiple Sclerosis and Parkinsons Society of Canterbury Inc. 
and the Christchurch Hospital Neurology Department to identify and categorise MS 
patients in detail. 
2. To measure the medical, personal and societal economic costs for each MS patient. 
3. To assess the changes in costs for patients over time and thereby indicate what costs 
savings may result from any intervention to slow progression of MS. 
 
To achieve the research objectives it was necessary to measure the economic costs associated 
with people who have MS.  Specifically, it was essential to examine the costs of exacerbations 
and/or the cost of disability. An exacerbation or relapse was defined as:  “the occurrence of a 
symptom or symptoms of neurological dysfunction, with or without objective confirmation, 
lasting more than 24 hours” (Poser et al., 1983).  A remission was defined as a definitive 
improvement in signs or symptoms, or both, for at least one month (Ibid.).  It must be noted that 
the assessments of costs in this research only focussed on economic costs and not on measuring 
the social or psychological costs stemming from the stresses caused by MS for both patients and 
their families. 
 
 
 
                                                
1 The MS Forum (1995) stated that direct costs relate to detection, treatment, prevention, rehabilitation and long-
term care, they are, the resources allocated to the treatment of MS. 
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1.4  Methods 
 
The research approach parallels methods considered when estimating the economic burden of a 
disease, as outlined by the MS Forum (1995).  For this study a prevalence approach was utilised, 
that is, costs were calculated for a given year, 1999.  The prevalence approach is appropriate for 
a study of MS costs, as it can be related to annual healthcare expenditure.  The data received was 
analysed using a bottom-up method, where the costs for the MS sub-population are established.  
The sub-population costs can then be extrapolated over a whole population to provide total 
(national) cost figures.  This study attempted to calculate the direct and indirect costs of MS, 
though did not attempt to establish the intangible costs2 of MS, as little is known about these 
costs.  Criteria for direct and indirect costs were based on descriptions provided by Lissovoy and 
Lazarus (1994) and the MS Forum (1995).  The criteria used were: 
 
Direct costs: 
• Treatment, prevention and care costs related to orthodox medical care only. 
• Additional services, equipment and other resources used to assist in the continuous living 
with MS. 
• Financial assistance provided by government agencies to people with MS to assist with 
health costs, supplement income and provide resources. 
• Other costs associated with accommodating a lifestyle with MS, such as home and 
vehicle modifications. 
 
Indirect Costs: 
• Alternative medical costs, which are generally self-directed by the individual.  These are 
considered non-essential costs by many professionals involved in MS treatment, though 
they do remain real expenses, even if elective, for the individual with MS. 
• Costs of informal assistance received by family, friends and other voluntary support. 
• Income lost by the individual due to illness associated with MS. 
• Other indirect costs, either not consolidated into the final analysis, or not considered in 
this research, include loss of income for partners and other family members, potential 
income tax loss for government and economic costs from loss of production for 
employers. 
 
The data collection method decided upon was a structured questionnaire to be completed in a 
one-to-one interview.  The patients who were included in the study were those with relapsing-
remitting multiple sclerosis (RRMS) on the computerised diagnostic database of the Neurology 
Department at Christchurch Hospital, who had been first diagnosed between 1984 and 1995 
inclusive as having clinically definite, laboratory supported definite, clinically probable or 
laboratory supported probable multiple sclerosis.  The criteria of Poser et al. (1983) were used to 
categorise subjects (See Appendix 1).  The hospital case notes of all living patients who were 
diagnosed as having multiple sclerosis between these years were ordered.  The Medical Records 
Department managed to locate 147 such records, which were reviewed by a neurologist and 
those fitting the above criteria were selected.  Patients with primary progressive multiple 
sclerosis were excluded but some of those in the study subsequently developed secondary 
progressive disease.  The notes of three of Christchurch’s neurologists were accessed, however 
the patients of a fourth neurologist were not available on the computerised database.  After 
intense investigation of records a total of 73 people (58 females and 15 males) were identified as 
matching the criteria for the research. 
 
                                                
2 Intangible costs are “the economic burden on the family that may arise from the psychological impact of the 
disease and stress related to disease symptoms” (MS Forum, 1995). 
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The next task was locating those identified as the research group.  The initial contact information 
was based on the addresses held with medical records at Christchurch Hospital.  Over half the 
address details were incorrect.  Telephone books for Canterbury, Westland and South 
Canterbury were used to update the contact information.  In some instances, all people with the 
same surname were telephoned and directory service assistance was used.  General Practitioners 
in the smaller, rural areas and Multiple Sclerosis Society staff in the three regions were also 
telephoned in attempts to contact some people.  Confidentiality and the privacy act were 
important issues, which added to the difficulty of locating people.  
 
Regional electoral roles were consulted for the outstanding addresses.  A small number of new 
addresses were confirmed.  For a significant number of cases the contact information remained 
outstanding.  It was decided, therefore, to wait for the new electoral role.  Overall, it took over a 
year to identify and locate all the people who were to be asked to participate in the research. 
 
The researchers aimed to contact all 73 potential participants by correspondence and follow up 
telephone calls.  The letter outlined the research, the nature of the proposed interview and 
questionnaire, with an emphasis that all responses would be anonymous.  It also explained that 
subjects would not be asked to become members of the Multiple Sclerosis and Parkinsons 
Society of Canterbury Inc.  After two weeks, a follow-up call was made to all subjects who 
received a letter to check their willingness to be interviewed and arrange a meeting. 
 
Almost all interviews were conducted in person and the remainder four interviews were 
conducted over the telephone.  Two of these participants were reluctant to be interviewed in 
person, one was seriously ill and awaiting surgery, and another lived in the North Island. 
Interviews were held in Timaru, Ashburton, Darfield, Rangiora, and the West Coast.  Apart from 
the telephone interviews, all but five interviews were held in the participant’s own home.  Three 
were held at the participant’s place of employment, one at a rest home where the person was 
living and one person elected to be interviewed in a coffee shop.  All interviews were conducted 
by the same researcher. 
 
Consent forms were completed at the interview, along with release forms for contacting relevant 
health professionals to confirm information, where relevant.  A few consent forms needed to be 
posted back to the interviewer.  In these situations, stamped self-addressed envelopes were 
provided.  Two consent forms were not returned after interview even after several follow-up 
letters and telephone calls.  Reimbursement of transport costs was available to any subject who 
wished to be interviewed at the interviewer's office. 
 
When there was any question that the interviewee may have cognitive difficulties, a spouse, 
partner or family member who was familiar with the individual’s situation, was asked to be 
present for the interview.  The spouse of one person, who had severe cognitive changes, was 
interviewed in place of the subject.  The MS staff member working with the family was also 
present.  
 
A total of 59 questionnaires were completed, that is, 81 per cent of all people identified as 
matching the research criteria. Of the 14 people who did not complete the questionnaire two 
people chose not to respond; ten people were not located; one person lived overseas; and one 
person was deceased.  In effect, the sample of 59 out of the original 73 was a sample of 59 out of 
the 61 available people.  The sample can be taken as representative of the research population 
and we will refer to it as the latter. 
 
In line with a main objective of the research, there were two groups: those diagnosed from 1984 
to 1989, inclusive (Group 1); and those diagnosed from 1990 to 1995, inclusive (Group 2).  
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Table 1 outlines the distribution of these two groups. Group 13 was the smaller in size with 24 
respondents (41 per cent) and Group 2 had 35 respondents (59 per cent). The purpose of the two 
groups was to establish the characteristics of the groups, and a comparison of their costs to 
ascertain differences over time.  
 
Table 1: Diagnostic Groups 
 
Group No. % 
Group 1 (1984-1989)* 
Group 2 (1990-1995) 
24 
35 
41 
59 
Total 59 100 
*Includes one from 1981 
 
 
All interviews, except for the first six used to pre-test the questionnaire, were performed in 1999.  
The questionnaire (See Appendix 2) was arranged into four cost sections of medical costs, 
personal care (resource) costs, employment and income costs, and other associated costs.  When 
completing the questionnaire care was taken to ensure only details of costs directly associated 
with the subjects' MS were included.   Other details relating to the participants condition, such 
as, when they were diagnosed and what symptoms they experienced, were also recorded. 
 
Visits to hospitals, GP’s and other health professionals for MS in the last six months were 
recorded, including needs assessments.  This timeframe was regarded as being a reasonable 
period for the respondents to be able to remember.  When calculating annual costs the figures 
provided were doubled. Medical hospital costs either as inpatient, outpatient or day-patient were 
obtained from hospital medical records.  Generally, these were over a three-year period leading 
up to the time of the research.  Annual figures were established by dividing individual totals by 
three.  It is also noted that costs in this section have been under-represented, as some expenses 
proved impossible to verify in hospital records.  For example, one respondent had suffered a 
hand injury at work as a result of numbness in the hand due to MS.  The subject attended the 
emergency department at Christchurch hospital and a day surgery at another, but no information 
about these visits could be obtained.  
 
Costs for prescribed medication were identified, as well as costs for treatment from alternative 
therapists and any other self-directed treatments.  The costs for prescribed medication were 
obtained by consulting a list of the base prices.  The head pharmacist at Christchurch Hospital 
provided this list.  Three community pharmacies were also contacted in order to reach an overall 
cost calculation for government and patient costs for each medication. 
 
The next section of the questionnaire covered personal care resources in the last six months, 
including whether the subject had been in alternative living care. The costs of resources (services 
and equipment) obtained from or used within the hospital systems within six months were 
recorded.   Service providers were consulted to confirm the accuracy of the costs received from 
the respondents. No changes were required to the information obtained at interview. 
 
The process of confirming costs with hospitals and service providers proved very time 
consuming.  It involved considerable contact with a wide range of health professionals and 
service providers who completed significant work on the researchers’ behalf. All were co-
operative and without their help information would not have been as accurate.   
                                                
3 One person included in Group 1 was diagnosed with MS in 1981, but did not meet the Poser et al. (1983) criteria 
until the 1984 - 1989 period. 
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Details of the respondents’ living arrangements were recorded.  Information was gained as to 
whether people with MS lived alone, and if not, who they lived with, whether anyone in the 
home provided assistance and what cost could be associated with that help.  Informal voluntary 
help from outside the household was also recorded. Informal assistance was calculated as an 
indirect cost with a value of $10.00 per hour.  Informal assistance of less than two hours per 
week was not recorded.  
 
The income and employment cost section identified who had experienced reductions in income 
due to MS, including reduced hours, time off through sickness or complete loss of employment.  
Those not in paid employment were asked why, and, if due to MS, how long they had not been 
working and their annual income at the time they left paid employment.  Where there was a 
partner involved, respondents were asked whether they had reduced or increased their paid 
employment hours, or left work temporarily or permanently because of the respondent’s MS.  
Maximum annual incomes for subject and partner, before the subject reduced hours or left paid 
employment, as well as current income for partner and subject were recorded.  This enabled a 
before and after income comparison. 
 
Details of any means tested benefits received because of MS were recorded.  Information 
regarding other income assistance from private grants, Accident Compensation Corporation, or 
the New Zealand Lottery Board was obtained. 
 
Expenditure on a wide range of options including home alterations in the last five years, sale of 
assets, moves to cheaper or more expensive housing, other privately funded services (such as, 
gardening and private home help), informal financial help from family, and items purchased or 
maintained was recorded.  In one case, a subject, living alone following a divorce, had moved 
from an old, high-maintenance house with stairs at the front and back entrances and a large 
garden, to a smaller, though more expensive, modern, one-level town house, with little garden.  
This had required a significant addition to the mortgage.   
 
Government funded home alterations in the last two years were also recorded.  A two-year 
period was chosen to ensure that hospital records would be available.  These costs were 
confirmed by contacting the occupational therapist authorising the work.  
 
The final section covered transport costs and included only those related to MS.  Upgrades of 
cars funded either privately or through government grants, hand control purchases, lottery 
grants, driving assessments and weekly total transport costs were included.  
 
While not all cost details were supported by official records, every effort was made to verify 
costs that had been incurred by the individuals.  Where no official details of hospital, GP or 
resource expenses could be obtained, the information was not included.  When calculating the 
overall costs for individuals and the entire research group it was expected that figures were of a 
conservative nature, as totals tended to be under-valuations of the actual costs experienced.  
 
 
1.5  Report Outline 
 
Throughout the report the economic cost information is presented in terms of direct and indirect 
costs.  For this research the separation between direct costs and indirect costs is based on criteria 
that were outlined in the methods section. 
 
The direct or indirect cost interpretations are applied in analysis in Chapters 3 and 4.  Before 
them, however, Chapter 2 outlines the characteristics of the people with RRMS that were 
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studied.  In line with an objective of the research the respondents are divided into two groups 
based on when they reached diagnostic criteria.  This is to enable comparisons of cost over time, 
which feature later in the report.  Some characteristics of the research population and diagnostic 
groups are examined.  Characteristics detailed include, where respondents were diagnosed, 
duration of MS, symptom range, age, living arrangements and employment status.  
 
Chapter 3 begins the lower level analysis of separate costs associated with the four main cost 
categories, namely: medical costs, resource costs, income and employment costs and other 
associated costs.  Each category is analysed by the main cost bearers, that is, the people with MS 
and the government.  Analysis also occurs by direct and indirect costs.  The cost category totals 
are carried over to the overall cost analysis in the following chapter. 
 
Chapter 4 is a higher level analysis of costs associated with MS.  By utilising the totals of the 
categories derived in Chapter 3 the overall costs are examined.  The first section examines the 
direct costs of MS by cost category by cost bearer.  An indirect cost analysis follows, though 
only personal indirect costs were recorded.  A comparison of the total indirect and direct costs of 
MS finishes this section.  The next section examines all costs together.  It avoids any distinction 
from what is considered a direct or an indirect cost.  The total costs are examined by cost 
categories as they stand for individuals and government, and as the final total of all cost 
categories.  Other analysis lists all the separate costs that make up the cost categories to ascertain 
the ten highest costs and the ten most commonly incurred costs.  The final section of this chapter 
compares the means of costs for people diagnosed from 1984 to 1989 (Group 1) and those from 
1990 to 1995 (Group 2).  The intention of this analysis is to test the relationship of cost with the 
time people have had MS.  Before the study it was assumed that a person’s costs would be 
higher the longer they had MS.  This hypothesis is not supported by these findings. 
 
For Chapters 3 and 4, the key economic information on the costs is presented in a standard table 
format (See Table Example).  The headings of the tables represent the key cost being analysed 
and discussed.  The first columns of the table present the numbers and percentages of the 
research population that responded to that particular variable.  The second category of 
information provides the mean calculated from the whole research population of 59 respondents.  
This corresponds with an aim of the report to present the costs as they apply to the entire 
research population.  Another central tendency figure, the median, is provided next, which is 
also applied across the research population. The next column presents the maximum figure for 
that variable. In many cases the maximum figure is representative of the range, as the minimum 
is mostly zero.  In some case there are negative minimum results that will be highlighted where 
applicable.  The final column is the total costs for that variable.  If readers wish to they can 
calculate the mean for those who responded by using the total cost column and response number 
data from column one.    
 
Table Example 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 $ % 
 
 
       
Total / Summary        
 
 
Chapter Five is the summary and conclusion of the report.  It reviews the information provided 
throughout the report and discusses some of the implications of the economic costs of MS in the 
Canterbury region and for the rest of New Zealand. 
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Chapter 2  
Results: Respondent Details 
 
 
2.1  Introduction 
 
The details of the respondents that participated in this study are outlined in this chapter.  Some 
areas analysed for the report cover the clinical features of respondents, including where their 
MS4 was diagnosed, the duration of the condition, and the symptoms associated with their 
disorder before and after diagnosis.  The analysis then focuses on characteristics of the 
respondents, including their age, living arrangements and employment status.  Most of the tables 
present the information for the total respondents and the two diagnostic groups: those diagnosed 
from 1984 to 1989, inclusive (Group 1); and those diagnosed from 1990 and 1995, inclusive 
(Group 2). 
 
 
2.2  Diagnosis and Symptom Details 
  
From the 59 people that participated in the study, 56 were able to state who diagnosed their MS.  
By naming who diagnosed the respondent with MS it was possible to identify where they were 
diagnosed.  This was based on knowledge of location of the doctors named.  Table 2 shows 53 
respondents (95 per cent) were identified as being diagnosed with MS in Christchurch.  Only 
three respondents were diagnosed outside Christchurch: two within New Zealand and one 
outside of New Zealand.  It should be noted, however, that these three had not fulfilled the study 
entry criteria until they re-presented with MS and were investigated in Christchurch. 
 
Table 2: Where Respondents Diagnosed 
 
Location Diagnosed No. % 
Christchurch 
Outside Christchurch 
Outside New Zealand 
53 
2 
1 
94 
4 
2 
Total 56 100 
 
 
Table 3 summarises the number of years since respondents first experienced MS symptoms, 
years since reaching the diagnostic criteria for RRMS and the gap between these.  With 1999 as 
the year of the study, the average respondents had experienced symptoms of MS for 14 years, 
with a range of respondents experiencing MS symptoms for four through to 42 years. The 
average since reaching diagnostic criteria was eight years.  The range of years since diagnostic 
criteria was from four to 18 years.  This signifies a broad range of people with MS and 
experiences of living with the condition.  The last duration statistic shows that, on average, a 
respondent had an interval of six years between their first symptoms and eventual diagnosis.  
One respondent experienced a 32-year gap between first symptoms and diagnosis. 
 
                                                
4 Generally, throughout the discussion of research findings (Chapters 2,3 and 4) and conclusions (Chapter 5), 
instead of the expression RRMS (relapsing-remitting multiple sclerosis) the abbreviation MS (multiple sclerosis) is 
used, though it implies the RR sub-group of the condition.  Also, it is important to note that people within other sub-
groups of MS were not included in the selected research population.  However, by the time of the interviews some 
people in the study may have advanced further in their condition since reaching relapsing-remitting diagnostic 
criteria. 
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When the same analysis was applied to the diagnostic groups the results were representative of 
their time with the condition.  Group 1, on average had 19 years since their first symptoms, 
while Group 2 had 12 years.  Group 1 averaged 12 years since reaching diagnostic criteria and 
Group 2 six years. 
 
Table 3: Years Since First Symptom(s) and Diagnosis  
 
Mean Min. Max.  
Category G1 G2 T. G1 G2 T. G1 G2 T. 
Years since first symptom 
Years since reaching diagnostic criteria 
Years between symptom & diagnosis 
19 
12 
6 
12 
6 
6 
14 
8 
6 
10 
10 
0 
4 
4 
0 
4 
4 
0 
42 
18* 
32 
29 
9 
25 
42 
18 
32 
* One person diagnosed as “possible” MS in 1981 
 
 
A first distinction to be assessed was the identification of the differences in the symptoms 
experienced by people with MS before and after reaching diagnostic criteria.  The establishment 
of the symptoms experienced by the groups and the total population is important for the analysis 
of economic costs.  The needs of the people with MS normally relate to the medication and 
assistance they require due to symptoms they experience.  That is to say, that different symptoms 
will have different economic consequences for people with MS.  This report does not place a 
value on the symptoms, as that would require a more in-depth study. 
 
Table 4 presents the most common symptoms experienced by respondents before they were 
diagnosed with MS.  Respondents were asked to state their primary symptom(s) before 
diagnosis.  The top five symptoms listed were: (1) sensory impairment (61 per cent); (2) fatigue 
(53 per cent); (3) vision change (47 per cent); (4=) weakness (39 per cent); and (4=) imbalance 
(39 per cent).  When separated into Group 1 and Group 2 there was a small difference in order of 
symptoms, and the inclusion of one other symptom.  Group 1’s top five symptoms were: (1) 
sensory impairment, (2=) vision change, (2=) mobility, (4) imbalance, (5=) fatigue and (5=) 
weakness, while Group 2’s top five symptoms were: (1) fatigue, (2) sensory impairment, (3) 
vision change, (4) weakness and (5) imbalance.  Sensory impairment, fatigue, vision change, 
weakness and imbalance symptoms featured in the top five of both groups and the total 
population.  The one difference was the inclusion of mobility, which was second equal as a 
symptom for Group 1. 
 
Table 4: Most Common Symptoms Before Diagnosis 
 
 Group 1 
(n=24) 
Group 2 
(n=35) 
Total 
(n=59) 
Symptoms No. % No. % No. % 
Sensory impairment 16 166 20 257 36 161 
Fatigue 9 5=37 22 163 31 253 
Vision change 11 2=46 17 349 28 347 
Weakness 9 5=37 14 440 23 4=39 
Imbalance 10 442 13 537 23 4=39 
Mobility 11 2=46 11 31 22 537 
Percentages not equal to 100 as multiple responses recorded. 
 
 
Table 5 shows the most common symptoms for the groups and total population after they were 
diagnosed with MS.  The top five symptoms experienced after diagnosis were: (1) fatigue (75 
per cent); (2) imbalance (69 per cent); (3) weakness (63 per cent); (4) mobility (59 per cent); and 
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(5) sensory impairment (56 per cent).  For Group 1 the order was: (1) mobility, (2=) fatigue, (2=) 
imbalance, (4) weakness and (5) co-ordination, and Groups 2’s order was: (1) fatigue, (2=) 
sensory impairment, (2=) imbalance, (4) weakness and (5) bladder dysfunction.  Fatigue, 
imbalance and weakness related symptoms feature in the top five of both groups and the total 
population.   
 
Table 5: Most Common Symptoms After Diagnosis 
 
 Group 1 
(n=24) 
Group 2 
(n=35) 
Total 
(n=59) 
Symptoms No. % No. % No. % 
Fatigue 18 2=75 26 174 44 175 
Imbalance 18 2=75 23 2=66 41 269 
Weakness 17 471 20 457 37 363 
Mobility 19 179 16 46 35 459 
Sensory impairment 10 42 23 2=66 33 556 
Spasticity 12 50 16 46 28 647 
Bladder dysfunction 8 33 18 551 26 744 
Co-ordination reduced  13 554 12 34 25 842 
Percentages not equal to 100 as multiple responses recorded. 
 
 
There were some differences in symptoms before and after diagnosis.   For Group 1 the change 
in symptoms from before diagnosis to after diagnosis saw the inclusion of co-ordination reduced, 
and the exclusion of sensory impairment and vision change.  For Group 2 vision change was 
included as a symptom before diagnosis, but not after diagnosis where it was replaced by bladder 
dysfunction.  For the total population it was vision change again that was not included in the 
after diagnosis top five.  It was replaced by mobility related symptoms.  It is important to note 
that for both groups and the total population there was a noticeable increase in the numbers of 
people experiencing the consistent symptoms of fatigue (total: before 53 per cent; after 75 per 
cent), imbalance (total: before 39 per cent; after 69 per cent), weakness (total: before 39 per cent; 
after 63 per cent) and mobility (total: before 39 per cent; after 59 per cent).  
 
 
2.3  Age Groups 
 
Table 6 presents the breakdown of the two diagnostic groups and the total research population 
by age groups. For the total population, most respondents were aged in their forties, that was, 
those “40 to 44” years old (24 per cent) and “45 to 49” years old (19 per cent).  The next highest 
age group followed from those in their forties to the “50 – 54” year olds (17per cent).  The 
youngest respondent was 27 years old and the oldest was 74 years.  The average respondent’s 
age was 46.5 years. 
 
When examining the difference between diagnostic groups there was a noticeable distinction in 
ages.  Most respondents diagnosed from 1984 to 1989 (Group 1) were in the 40 to 54 age group 
(sub-total 47 per cent).  However, Group 1 had a higher representation of people over 60 years 
(sub-total 30 per cent), while Group 2 had considerably less (sub-total 6 per cent).  This was 
further verified by the youngest person in Group 1 being 34 years, while the oldest was 74 years.  
The average age in Group 1 was 51 years.  Group 2, those diagnosed from 1990 to 1995, also 
had the most people in the 40 to 54 year range (sub-total 68 per cent).  The youngest person in 
Group 2 was 27 years and the oldest was 62 years.  The average age of Group 2 was 44 years.   
The data confirms that Group 1 respondents tended to be older than the Group 2 respondents. 
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Table 6: Respondents’ Ages 
 
Group 1 Group 2 TOTAL  
Age Groups No. % No. % No. % 
25 – 29 0 0 2 6 2 3 
30 – 34 1 4 4 11 5 9 
35 – 39 4 17 2 6 6 10 
40 – 44 3 13 11 31 14 24 
45 – 49 3 13 8 23 11 19 
50 – 54 5 21 5 14 10 17 
55 – 59 1 4 1 3 2 3 
60 – 64 3 13 2 6 5 9 
65 – 69 3 13 0 0 3 5 
70 + 1 4 0 0 1 2 
Totals 24 102* 35 100 59 100 
*Column not equal to 100 due to rounding. 
 
 
2.4  Living Arrangements 
 
Later in the discussion economic considerations are made for the informal assistance provided 
by family members and the income costs to partners who may have to change, reduce or leave 
work to support the person with MS.  For those reasons, understanding the living arrangements, 
that is, with whom people with MS live, is very important. Multiple Sclerosis not only affects 
the person with the condition, but also those that live with and support the individual.  The 
details on the living arrangements assist in understanding the extent of these flow-on costs. 
 
The range of living arrangements is presented in Table 7.  From the 59 respondents only four 
people (7 per cent) stated that they lived alone.  The greatest proportion (23 people, 39 per cent) 
lived with their partner and children. When separated into Group 1 and Group 2 the highest 
representation was in living with a partner or spouse (42 per cent) for Group 1, and partner and 
children (45 per cent) for Group 2.  The other living arrangements included living with children 
only (14 per cent), other family based arrangement (5 per cent) a hospital or rest home (2 per 
cent), and other arrangements, such as, flatting (3 per cent).  Ninety-three per cent of people with 
MS lived with other people at the time of the study.  The nature of MS and the known affects on 
individuals during times of attacks and severe fatigue will flow on to those in nearby proximity 
as the need for physical assistance increases. 
 
Table 7: Respondents’ Living Arrangements  
 
Group 1 Group 2 Total People live with… 
No. % No. % No. % 
Live alone 2 8 2 6 4 7 
Spouse / Partner 10 42 8 23 18 30 
Children only* 3 13 5 14 8 14 
Partner and children* 7 29 16 45 23 39 
Parents 0 0 1 3 1 2 
Other family arrangement 2 8 0 0 2 3 
Hospital / Rest home 0 0 1 3 1 2 
Other e.g. flat with friends 0 0 2 6 2 3 
Totals 24 100 35 100 59 100 
*Includes adult children > 18 
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2.5  Employment Situation 
 
Another important component in the analysis of MS costs is the indirect costs associated with 
loss of income for people with MS.  The first step in the analysis of income losses was to 
establish the employment situation of people included in the research.  Table 8 shows that 31 
respondents (53 per cent) were in paid employment at the time of the study.  Twenty-eight 
respondents (47 per cent) were not in paid employment.  When the breakdown of employment 
status was applied across the two diagnostic groups the ratios appeared different.  Group 1 had 
more people not in paid employment (16 people or 67 per cent) and Group 2 had more people in 
paid employment (23 people or 66 per cent). 
 
Table 8: Respondents Currently in Paid Employment  
 
Group 1 Group 2 Total Paid 
Employment No. % No. % No. % 
Yes 
No 
8 
16 
33 
67 
23 
12 
66 
34 
31 
28 
53 
47 
Total 24 100 35 100 59 100 
 
 
The people not in paid employment (n=28) were asked the reason they were not earning (Table 
9).  Twenty-one people (75 per cent) not in paid employment attributed this to having MS.  MS 
fatigue was the most common factor that prevented working.  The remainder of people not 
working were either retired (14 per cent) or had another reason (11 per cent), such as being made 
redundant or looking after their children.  There were 16 people in Group 1 that were not in paid 
employment.   For ten of these people it was due to MS; five were retired and one was not 
working for another reason.  Twelve people from Group 2 were not in paid employment.  Eleven 
people were not working due to MS, and one was not in paid employment for another reason. 
 
Table 9: Reasons Respondents Not in Paid Employment 
 
Group 1 Group 2 Total Reason Not 
Working No. % No. % No. % 
MS Related 
Retired 
Other 
10 
5 
1 
63 
31 
6 
11 
0 
1 
92 
0 
8 
21 
4 
3 
75 
14 
11 
Total 16 100 12 100 28 100 
 
 
The people not working were also asked details on how long since they had been in 
employment.  The analysis shows the average time people had been out of paid employment was 
7.5 years, with a range from under one year to 28 years.  For Group 1 the mean period for being 
out of employment was nine years, with a range from under one year to 27 years.  For Group 2 
the mean period for being out of paid employment was six years, with a range of under one-year 
to 28 years. 
 
The people with MS who were in paid employment (n=31) were asked whether they were full-
time, part-time or self employed.  Table 10 shows that for the total population there was an even 
split of 13 people working full-time and 13 people working part-time.  Four people were self-
employed, while one person did not specify their arrangements.  The people with MS in paid 
employment were also separated into Group 1 (n=8) and Group 2 (n=23).  Only two people in 
paid employment from Group 1 were in full-time employment, while the remaining six people 
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were part-time.  For Group 2, 11 people were full-time, seven were part-time, four were self-
employed and one person’s employment arrangement was unspecified. 
 
From the total population, the 13 people in full-time employment worked weekly hours ranging 
from 35 to 70 hours.  There was an average of 42 hours per week worked by people with MS in 
full-time work.  For the 13 people in part-time work the weekly hours ranged from 3 to 35 hours, 
with an average of 23 hours per week.  From the remaining self-employed individuals, two 
worked under five hours a week, while the other two worked a 30 and a 50-hour week. 
 
Table 10: Respondents’ Employment Arrangement 
 
Group 1 Group 2 Total Employment 
Arrangement No. % No. % No. % 
Full-time 
Part-time 
Self-employed 
Unspecified 
2 
6 
0 
0 
25 
75 
0 
0 
11 
7 
4 
1 
48 
31 
17 
4 
13 
13 
4 
1 
42 
42 
13 
3 
Total 8 100 23 100 31 100 
 
 
2.6  Summary 
 
The analysis shows that 95 per cent of all the people who participated in the study had an initial 
diagnosis of MS in Christchurch.  The average respondent had experienced MS symptoms for 14 
years and it had been eight years since they reached the diagnostic criteria used for this study.  
The average respondent also experienced a gap of six years between their first symptoms and 
eventual diagnosis.  Before diagnosis the most common symptoms experienced by respondents 
were sensory impairment, fatigue or vision change.  After diagnosis the most common 
symptoms were fatigue, imbalance or weakness.  Most respondents were aged in their forties, 
with an average age of 46.5 years.  Eighty-three per cent of respondents lived with a partner or 
spouse and/or their children.  Only seven per cent of respondents lived alone. 
 
When the research population was separated into diagnostic groups there were some differences 
between them.  Group 1 respondents tend to be older and were less likely to be in paid 
employment than Group 2 respondents.  This suggests that people in Group 1 may be more 
dependent on family and government for assistance in living with MS. The two lists below 
highlight these and other differences: 
 
Group 1: Twenty-four people matched the study diagnostic criteria between 1984 to 1989. 
Their main symptoms before diagnosis were: sensory impairment, vision change 
and mobility. 
  Their main symptoms after diagnosis were: mobility, fatigue and imbalance. 
  Eleven people (47 per cent) were aged 40 to 55 years old. 
  Seven people (30 per cent) were over 60 years old. 
  The youngest was 34 and the oldest was 74, while the average age was 51. 
  Twenty people (84 per cent) lived with a partner or spouse and/or children. 
  Two people (8 per cent) lived alone. 
  Eight people (33 per cent) were in paid employment; 16 people (67 per cent) were 
  not in paid employment. 
  From those not working, ten people (63 per cent) were not working due to MS. 
 From those working, two people (25 per cent) were full-time and six were part-
 time (75 per cent). 
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Group 2: Thirty-five people matched the study diagnostic criteria between 1990 to 1995. 
Their main symptoms before diagnosis were: fatigue, sensory impairment and 
vision change. 
  Their main symptoms after diagnosis were: fatigue, imbalance and sensory 
  impairment. 
  Twenty-four people (68 per cent) were aged 40 to 55 years old. 
  Two people (6 per cent) were over 60 years old. 
  The youngest was 27 and the oldest was 62, while the average age was 44. 
  Twenty-nine people (82 per cent) lived with a partner or spouse and/or children. 
  Two people (6 per cent) lived alone. 
  Twenty-three (66 per cent) were in paid employment; 12 people (34 per cent) 
  were not in paid employment. 
  From those not working, 11 people (92 per cent) were not working due to MS. 
 From those working, 11 people (48 per cent) were full-time; seven were part-time 
 (31 per cent); four (17 per cent) were self-employed; and one (4 per cent) was 
 unspecified. 
 
Having described respondent details in order to provide important background information, the 
report moves on in Chapter 3 to the cost categories relating to medical, resources, income and 
other costs. 
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Chapter 3 
Results: Costs Associated with Multiple Sclerosis 
 
 
3.1  Introduction 
 
The findings of the cost categories, around which the questionnaire was based, are analysed in 
this chapter.  The categories are medical costs, resource costs, income and employment costs and 
other associated costs5.  The main analyses are by cost category and cost bearer.  Indirect and 
direct costs are also incorporated into the analysis.  All the costs are presented as either 
confirmed costs or estimated costs for the year 1999.  The information provided will be for the 
total research population.  An analysis of the costs by the two diagnostic groups does not occur 
until Chapter Four. 
 
The medical costs section examines all the costs associated with the medical control of MS.  The 
medical costs were analysed by three perspectives.  First, the direct medical costs of GP and 
prescription costs paid by the individuals with MS.  Second, the direct medical costs of hospital 
treatment, other health professionals and prescription costs paid by the government through 
health funding arrangements.  Third, the indirect costs, or elective costs, associated with an 
individual’s decisions to try alternative treatments and medication. 
 
The resource costs section divides the cost of resources (including services) utilised by the 
people with MS, as those paid for by the individuals and those paid by the government.  It also 
offers insight into the indirect costs associated with informal assistance from friends, family and 
other volunteers. 
 
The next section summarises the indirect income cost (lost income and lost income potential) of 
individuals.  It then outlines the direct costs to government in supplementing this income loss, 
either through a range of benefit options, ACC assistance or other forms of grants.  The costs to 
the individual and to the government are amalgamated to establish a total income cost of MS. 
 
The final cost category is other associated costs.  Here the costs of upgrading or altering homes 
and vehicles, plus the transport costs associated with MS, are summarised. 
 
 
3.2  Medical Costs 
 
Direct medical costs are hospital, general practitioner (GP) and prescription costs as they are for 
the person with MS and the government.  Table 11 shows the annual direct medical costs 
incurred by people with MS, specifically the personal costs of GP visits and prescriptions to 
manage and/or treat symptoms.  The total paid in 1999 for all personal medical costs by all 
respondents came to $21,447.  This figure averages $364 per person (median = $80) per year for 
direct medical related costs.  It is important to note that not all of the respondents expected to 
pay any personal costs for 1999, as many considered themselves to be quite healthy.   Two thirds 
(64 per cent) of respondents listed personal medical costs. The maximum amount paid in direct 
treatment costs by any one of the individuals surveyed was $6,920.  This person had received 
advice from their GP to try a range of alternative medicines, which were included as direct 
                                                
5 The raw cost data was collected in various time frames, for example, GP costs over six months, hospital costs over 
two years and home alteration costs over five years.  The timeframe variations result from considerations about the 
ability to collect information from third party sources and the ability of people to recall costs over time.  The 
analysis of each cost type and the ability to collect and confirm information were considered before questions were 
designed about cost categories. 
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prescription costs as a result.  The next highest personal direct medical cost was $2,840.  This 
person’s costs were associated with a high number of GP visits at a cost of $960, and 
prescription costs of $1,880 which were inflated by use of Phenylalanine, also a non-orthodox 
treatment, valued at $1,660. 
 
Table 11: Total Personal Direct Medical Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
GP visits 
Prescriptions 
34 
29 
58 
49 
$168 
$196 
$44 
$0 
$1,920 
$5,000 
$9,902 
$11,545 
46 
54 
Total / Summary 38 64 $364 $80 $6,920 $21,447 100 
 
 
Information about three government costs associated with the medical treatment of MS was 
obtained.  The first was hospital treatment costs which relate to the cost of treating MS for acute 
exacerbations, other illnesses, events associated with MS, such as urinary tract infections and 
falls, or a combination of these.  The respondents were asked to report the number of relapses 
they experienced for the years 1996, 1997 and 1998, whether they had received treatment and 
the form of treatment they received.  This information was cross-referenced with hospital 
records and a costing of each patient’s treatment was established.  The figures were then divided 
by three to establish a one-year summary of the costs of treating MS.  Many relapses noted by 
the subjects were not treated or notified to any health professional and were managed informally 
and without cost to the subject or the government.  The second government medical costs are 
associated with the consultation of other medical professionals, such as, other physicians, 
physiotherapists, occupational therapists and needs assessors.  The third are the proportion of 
prescription costs that were paid for by the government drug funding agency, Pharmac. 
 
Table 12 shows the figures for each of the three main government costs.  The largest cost was 
the amount paid in hospital treatment, with a total of $27,627 paid for all respondents. The mean 
hospital treatment cost to government for each respondent was $468 a year. The next highest 
was the cost of other health professionals, such as occupational therapists and physiotherapists, 
with a total of $11,331 for 1999. 
 
Overall, the government was estimated to have paid $47,016 in medical related cost for all 
respondents in 1999.  The mean paid per person with MS was $797 (median = $110) a year.  The 
maximum paid by the government in medical costs for any one individual was $4,395.  This was 
the same maximum figure paid in hospital treatment costs.  Hospital costs were consistently the 
highest component of government direct medical cost totals.  Fifty nine per cent of respondents 
had partial or complete medical cost paid for by government. 
 
Table 12: Total Government Direct Medical Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Hospital treatment6  
Other health professionals 
Prescriptions 
22 
15 
21 
37 
25 
36 
$468 
$192 
$137 
$0 
$0 
$0 
$4,395 
$3,856 
$992 
$27,627 
$11,331 
$8,058 
59 
24 
17 
Total / Summary 35 59 $797 $110 $4,395 $47,016 100 
                                                
6 Hospital costs are an aggregate of all costs incurred by the MS sufferer for various types of treatment at inpatient 
and outpatient levels.   Does not include Interferon treatment, as it was unavailable in 1999. 
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Table 13 is a summary of total direct costs paid for by the people with MS and the government 
based on the results presented in Tables 11 and 12. It was established that 41 respondents (70 per 
cent) included in this study incurred some form of medical cost, whether it was for treatment, 
other health professional consultation or prescription costs.  More people paid their own medical 
costs (64 per cent) than had them paid for by the government (59 per cent).  Government 
medical costs ($47,016), however, were over twice the personal medical costs ($21,447).  The 
average medical cost for the whole study group was $1,161 (median = $601), with a total of 
$68,463 paid for the year 1999.  The highest direct medical cost of $8,540 was for the person 
with $5,000 in alternative medication prescriptions.  The second highest direct medical costs 
were $4,909.  This was the person with the second highest personal medical costs of $2,840, plus 
government assisted medical costs of $2,069. 
 
Table 13: Total Direct Medical Costs by Cost Bearer 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Personal direct  medical  
Government direct medical  
38 
35 
64 
59 
$364 
$797 
$80 
$110 
$6,920 
$4,395 
$21,447 
$47,016 
31 
69 
Total / Summary 41 70 $1,161 $601 $8,540 $68,463 100 
 
 
Not everyone with MS settles for “mainstream” treatment options.  Many people try alternative 
medication or treatment methods, or both.  These costs have been separated from the regular 
treatment costs, as they may be considered elective.  Nonetheless, there were considerable 
numbers of people (n=26, 44 per cent) who tried alternative medications or treatment outside 
those provided by the health system.  
 
Table 14 represents the costs of alternative therapy and self-directed medication costs incurred.  
Alternative therapies are treatment methods engaged by individuals, outside those that are 
provided by the health system, as outlined for direct medical costs.  Examples of alternative 
therapies listed by respondents include kinesthesiologists, naturopaths and osteopaths.  Common 
forms of self-directed medications used by people with MS were vitamins B, C and E, amino 
acids, evening primrose oil, bee pollen, garlic, other herbal remedies and the Cari Loader 
programme.   Forty two per cent of the respondents spent money on self-directed alternative 
medications.  This summed to $14,518 during the year of the study.  This figure is the primary 
cost in the overall total of $17,068 spent on medical alternatives, with an average of $289 per 
year spent by each respondent.  The maximum paid by one person was $5,400.  These costs 
consisted of $3,000 for a Cari Loader programme and $2,400 in naturopath costs.  The next 
highest cost for alternative treatment was $1,200. 
 
Table 14: Total Personal Indirect Medical Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median
(n=59) 
Max. 
 Cost % 
Alternative treatment  
Self-directed medication 
7 
25 
12 
42 
$43 
$246 
$0 
$0 
$650 
$5,400 
$2,550 
$14,518 
15 
85 
Total / Summary 26 44 $289 $0 $5,400 $17,068 100 
 
 
Table 15 combines the overall personal medical costs, whether they were professionally directed 
or self-directed treatments, as presented in Tables 11 and 14.  A total of $38,514 was paid by 
individuals for the treatment of MS during 1999.  This averages to $653 per respondent (median 
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= $256).  The maximum paid in medical costs by any one individual was $7,440.  This, again, 
was the person with high medication costs associated with regular use of alternative medications 
prescribed by a GP.  The next highest personal medical costs were $5770, followed by $2,840.  
In 1999, 46 respondents (78 per cent) personally paid medical costs that stemmed from either 
their initiative or from health professional directions. 
 
Table 15: Total Personal Medical Costs  
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Direct medical  
Indirect medical 
38 
26 
64 
44 
$364 
$289 
$80 
$0 
$6,920 
$5,400 
$21,447 
$17,068 
56 
44 
Total / Summary 46 78 $653 $256 $7,440 $38,514* 100 
*Does not equal sum of totals due to rounding. 
 
 
Table 16 summarises all the medical costs associated with MS.  These are all personal and 
government direct medical costs and all personal indirect medical costs.  Eighty-one per cent of 
people experienced medical costs related to the treatment of their MS.  The greatest total cost 
was paid for by government at $47,016.  However, when combining personal direct and self 
directed treatments the total was $38,514, which was a difference of only $8,500.  This indicates 
that for many people living with MS they pay almost as much as that covered by the government 
to assist in alleviating the effects of MS.  People with MS are also prepared to pay almost similar 
overall amounts in alternative treatment options, as they do for orthodox medical treatment. 
 
For each person included in the study an average annual cost of $1,450 (median = $731) can be 
attributed to medical related treatment.  The maximum in medical related treatment was $10,165.  
This person paid $370 in GP costs, plus $5,400 in self-directed alternative treatments.  Further, 
the government paid $4,395 in hospital treatment, which was associated with regular visits to a 
neurologist. The next highest medical costs incurred by individuals were $9,060 and $5,104. 
 
Table 16: Summary of All Medical Costs by Cost Bearer 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Personal direct medical  
Government direct medical  
Personal indirect medical 
38 
35 
26 
64 
70 
44 
$364 
$797 
$289 
$80 
$110 
$0 
$6,920 
$4,395 
$5,400 
$21,447 
$47,016 
$17,068 
25 
55 
20 
Total / Summary 48 81 $1,450 $731 $10,165 $85,531 100 
 
 
3.3  Resource Costs 
 
This section examines the costs of resources utilised by people living with MS.  Resources 
include services, equipment, and other items (and maintenance of equipment and items), that are 
used to assist people with MS.  Table 17 is a summary of the resource costs as paid for by either 
the people with MS or by the government, mainly through Health Funding Authority (HFA) 
arrangements.  The first row shows the resource costs paid for by the individual.  This is a sum 
of services, items and maintenance that were not supported by health funding arrangements.  
Examples of services paid for by the individual include gardening help, meals on wheels, private 
home help, childcare and personal help (such as, daily showering).  Items and equipment that 
may be paid for, and not assisted by central funding, include shoes, catheters, walking frames, 
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incontinence pads, shower stools and garage door openers.  Respondents were asked to provide 
details of purchases they had made in the last two years (1998 and 1999).  The total figure was 
divided by two to provide an annual cost of items and equipment included in resources costs.  
From the population 56 per cent had paid for resources.  The total spent on resources was 
$55,334, with a maximum of $8,623 paid by one person.  The mean over the entire research 
population was $938 per person.  
 
The second row represents the resource costs paid by the government, mostly through the HFA 
that was still in existence in 1999.  Assisting services that were paid for through the HFA 
included, domiciliary occupational therapists and physiotherapists, district nurse visits, needs 
assessment, personal and domestic support.  Some of the more common equipment paid for were 
wheelchairs and elbow crutches.  The total amount paid in resource costs by the health authority 
calculated into an annual figure was $118,206.  The mean was $2,003 per person, with a 
maximum cost of $23,632 paid for one person with MS.  Only one third (32 per cent) of 
respondents received financial assistance in resources. 
 
Overall, 66 per cent of the people included in the study incurred some form of resource related 
expense.  A total of $173,540 was paid by people with MS and the government, with a mean 
resource cost of $2,941 (median = $520) per person being incurred. 
 
Table 17: Total Direct Resource Costs by Cost Bearer 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Personal direct resources  
Government direct resources 
33 
19 
56 
32 
$938 
$2,003 
$140 
$0 
$8,683 
$23,632 
$55,334 
$118,206 
32 
68 
Total / Summary 39 66 $2,941 $520 $29,772 $173,540 100 
 
 
For people with MS, not all assistance is delivered through formal channels that incur direct, 
tangible costs.  Often assistance comes from family, friends and other voluntary workers that are 
not direct, “out of pocket expenses”, though a number of people do pay some form of “pocket 
money” for chores.  An attempt was made to place a value on costs associated with this informal 
work.  In the research the hourly rate attributed was $10, with any relevant work over a 
minimum of two hours per week being included.  There may be contention about placing a 
dollar value on some daily tasks, for example, for domestic chores normally shared amongst 
family members.  People were asked, nevertheless, to value the work performed by spouses, 
children, other family members and friends, which they were unable to do themselves due to 
MS.  Table 18 outlines these cost results. Twenty-nine respondents (49 per cent) provided details 
of informal assistance.  A total figure of $195,420 was established for this unofficial cost over a 
one-year period, which calculated a mean indirect cost of $3,312 per person in the study. The 
highest amount claimed in the unofficial capacity was $29,120 by one female respondent who 
was receiving full-time care from her husband. 
 
Table 18: Total Personal Indirect Resource Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Family assistance 
Other assistance 
25 
7 
42 
12 
$3,054 
$258 
$0 
$0 
$29,120 
$8,400 
$180,180 
$15,240 
92 
8 
Total / Summary 29 49 $3,312 $0 $29,120 $195,420 100 
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3.4  Income and Employment Costs 
 
The questionnaire examined the indirect (personal only) and direct (government only) costs of 
lost income for people with MS.  A person may be in permanent employment before the onset of 
MS, but miss days, reduce working hours, or leave work altogether due to being unwell.  There 
are also income effects for the spouses and partners of people with MS.  Further, the cost of lost 
income spreads to government responsibility as it pays the various benefit entitlements for 
people whose employment or income status has altered as a result of having MS.  MS has the 
potential to have a dramatic impact on the economic lives of many people, even if the lost 
income is supplemented with social welfare benefits and other payments.  For many people there 
is a loss of income from the time of the onset of symptoms associated with MS.  It is expected 
that the greater the symptoms of MS in an individual’s life the greater the impact on the income 
earning potential.  Another association with the cost of MS is the loss of production that may be 
experienced by some companies, due to staff not being available to fully meet output 
requirements, though this is not examined in this research. 
 
This section first looks at the costs of lost employment for the people with MS and the 
government.  The totals presented here are carried over to analysis of overall totals in Chapter 4.  
The section then presents the costs of lost employment to the partners of people with MS.  The 
aim is to highlight that economic consequences of MS stretch beyond the individual with the 
condition.  Due to a lack of responses regarding the costs to partners, this information will not be 
carried over to the following chapter. 
 
 
3.4.1  Personal and Government Income and Employment Costs 
 
Reasons for income lost by individuals were categorised into: days missed at work, income lost 
through reduced working hours and income lost due to loss of permanent paid employment all 
due to illness associated with MS.  The value of working days lost was established by personal 
details of days that had been missed due to MS in the last six months.  A value was placed on 
this time off using daily or hour rates based on normal wages or income.  Not all days lost 
through sickness are covered by the individual, as many have sick-day allowances as part of 
their employment contracts.  The assumption, however, is that the majority of the time lost 
through sickness is covered by the individual, because many have no remaining allotment due 
time with MS.  
 
Six people stated that they had missed days from their job in the last six months due to MS.  The 
largest number of days missing for any one person was 60 days, while two people experienced 
five sick days.  The total number of days lost for these six people was 123 days in six months.  
To establish an annual figure, the cost was multiplied by two.  Table 19 shows that a total value 
of $30,770.  The average was $521 per person involved in the research.     
 
Many people with MS manage to maintain permanent work, though some can only work part-
time.  Respondents were, therefore, asked whether they had reduced the number of hours they 
work as a result of MS.  Fifteen people (25 per cent of all respondents, and 48 per cent of all 
people in paid employment) had reduced work hours at some time.  This had occurred over a 
period of one to 16 years, with the average time experienced of reduced hours being six and a 
half years. Two of the fifteen respondents, had returned to previous working arrangements and 
one person was no longer working.  From the remaining 12 respondents who had reduced work 
hours, nine (15 per cent) provided details about their decreased hours, which ranged from two 
and a half hours to 35 hours a week.  The average for the nine people was a weekly reduction of 
12 hours.  While nine respondents provided details of their reduced hours, ten respondents (17 
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per cent) provided details on income lost through work hours reduced.  From these the annual 
sum lost was $61,990.  Over the population (n=59) this gave a mean of $1,051 per person. The 
maximum income lost through hours recorded for any one individual was $12,600.   
 
The potential annual income lost of the 21 people who had stopped working because of MS (See 
Table 9, Chapter 2) is based on the difference between their earlier income less the income they 
received at the time of the study7.  The total income potential lost was $275,278, which was 75 
per cent of the total.  Over all respondents there was a mean income loss of $4,666 per person.  
The maximum income difference experienced by a respondent was $90,228. This person was 
self-employed before developing MS.  The next highest personal indirect income costs were 
$34,520 and $27,000. Two people were marginally better off financially.  The total cost of lost 
income figures show that 28 respondents (47 per cent) experienced a loss of income.    The total 
lost was $368,038, which averaged to $6,238 for all respondents. 
 
Table 19: Total Personal Indirect Income Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Working days lost 
Reduced hours 
Annual income lost 
6 
10 
161 
10 
17 
27 
$521 
$1,051 
$4,666 
$0 
$0 
$0 
$18,000 
$12,600 
$90,2282 
$30,770 
$61,990 
$275,278 
8 
17 
75 
Total / Summary 281 47 $6,238 $0 $90,2282 $368,038 100 
1. Not including two people better off; 2. Minimum (-$8000), Range $98,228; 
 
 
Further details were sought on the income status of the people who left work due to MS.  From 
the 21 people who left work because of MS, 19 were able to indicate their annual income when 
they were forced to finish paid employment.  The mean income at the time of leaving work was 
$22,398, with a range from $4,160 to $99,840.  These figures become more relevant when 
compared to income figures of these same people at the time of the study. Seven people stated 
that at the time of the study they had no income, while the remainder had benefit income ranging 
from $2,626 to $22,860.  The mean income for people who have lost paid employment due to 
MS was $8,013.  This was a reduction of the mean income of people not in paid employment of 
$14,385 per annum. 
 
The cost of lost income borne by the government is primarily reflected through the benefits and 
compensation provided to supplement income shortfalls. Government benefits are supplied 
through various sources, such as, sickness and invalid’s benefits, disability allowances, 
community services and high use cards and accommodation allowances.  Thirty respondents (51 
per cent) received some form of benefit assistance from the government, however only 21 (36 
per cent) was because of MS (See Table 20).  The total benefit assistance paid to people in the 
study because of MS was $223,475, which averages to $3,788 per respondent.  Seven people had 
received ACC assistance, and only one had received a grant8.  The total financial assistance paid 
by government agencies was $239,336, with the average per respondent being $4,056.  The 
maximum paid for any one person was $22,860, which was a benefit only.  The next six highest 
government income costs ranged from $19,039 to $17,284.  Only one of these six did not 
completely consist of benefit assistance.  
 
 
                                                
7 Not all of the 21 people who had stopped work provided income details. 
8 To assist in the purchase of a scooter 
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Table 20: Total Government Direct Income Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Benefit assistance 
ACC 
Grants 
21 
7 
1 
36 
12 
2 
$3,788 
$167 
$101 
$0 
$0 
$0 
$22,860 
$8,834 
$5,995 
$223,475 
$9,866 
$5,995 
93 
4 
3 
Total / Summary 24 41 $4,056 $0 $22,860 $239,336 100 
 
 
In many cases, the loss of income had a two-fold effect on the overall income cost, that is, there 
was less income for the individual plus there was government expenditure in supplementing the 
lost income9.  For example, the maximum total income cost for one person was $108,674 (See 
Table 21).  This incorporated a personal income loss of $90,228 plus government assistance of 
$18,446 (benefit and ACC).  The next highest income costs for individuals were $47,042 and 
$43,786.  Table 21 summarises the total income costs for both individuals and government.  
Sixty-one per cent of respondents detailed some form of income cost.  The total income cost in 
one year for the respondents was $607,374.  The average was $10,294, with a median of $4,948.  
The proportion of personal indirect income costs (61 per cent) was higher than government 
direct income costs (39 per cent). 
 
Table 21: Total Income Costs by Cost Bearer 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Personal indirect  income  
Government direct income 
281 
24 
47 
41 
$6,238 
$4,056 
$0 
$0 
$90,2282 
$22,860 
$368,038 
$239,336 
61 
39 
Total / Summary 353 61 $10,294 $4,948 $108,6744 $607,374 100 
1. Not including two people better off; 2. Minimum (-$8,000), Range $98,228; 
3. Not including one person better off; 4. Minimum (-$2,834), Range $111,508. 
 
 
3.4.2  Partners’ Loss of Employment Costs 
 
The information about living arrangements showed whether people were supported by a spouse 
or partner.   Forty-two people (71 per cent) were living with a partner, while 17 people (29 per 
cent) did not have the support of a partner  (See Table 22).  However, there were only four 
people living alone.   
 
Table 22: Respondents with Support of Partner or Spouse 
 
Partner No. % 
Yes 
No 
42 
17 
71 
29 
Total 59 100 
 
 
                                                
9 It is acknowledged that there may be a case for double counting of both personal income lost, and payments by 
government to offset lost income.  One is an economic cost (income lost) and the other (government payments) is a 
transfer.  For our purposes both are considered expenses of MS, therefore it is appropriate to add them together. 
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Support from partners can be physical, emotional and financial, therefore there can also be 
detrimental consequences on these aspects.  A partner may be forced to take time off work, 
reduce their hours or leave work altogether to assist the person with MS.  There are also 
circumstances of increasing work hours and other commitments to better financially 
accommodate the personal costs associated with living with MS.  It is assumed that many of the 
partners that have left work altogether are now receiving some form of benefit assistance. 
 
In Table 23 it is established that from the 42 partners, 31 experienced a change of income as a 
result of supporting the person with MS.  Eleven people left work temporarily, while four left 
work permanently.  Ten people reduced their working hours to assist.  Six people increased their 
work hours, and correspondingly their income, as a result of their partner’s MS condition.  In 
total, 25 partners of people with MS experienced reduced incomes. 
 
Table 23: Why Partners’ Income Changed 
 
Partners’ Income Change No. % 
No change / not indicated 
Left work permanently 
Left work temporarily 
Reduced work hours 
Increased work hours 
11 
4 
11 
10 
6 
26 
10 
26 
24 
14 
Total 42 100 
 
 
There was a lack of information to properly assess partners’ economic costs of lost income or 
productivity.  Many respondents chose not to, or were unable to, provide details of their 
partners’ income.  This has meant that a reasonable approximation of lost income for partners 
has not been calculable.  Table 24 shows the information about income lost by partners that was 
available.  Nineteen respondents (45 per cent of those with partners) provided details of their 
partners’ income changes due to the respondents MS.  Only 17 respondents (40 per cent of those 
with partners) were able to provide details of their partners’ income losses, while the research 
established that 25 partners (60 per cent of partners) experienced an income loss. From the 
information provided, there was a total loss of partners’ income of $192,812 for the year 1999.  
The average income loss for partners across the entire sample of 59 people was $3,268.  The 
maximum loss for one person was $36,000. While the income loss figures for partners have not 
been carried to any final totals, this information does prove that the economic impact of MS is 
not just for the patient and the government. 
 
Table 24: Total Partners’ Indirect Income Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Partners’ income loss 
Partners’ other income loss 
111 
10 
19 
17 
$2,332 
$936 
$0 
$0 
$36,0002 
$16,640 
$137,562 
$55,250 
71 
29 
Total / Summary 173 29  $3,268 $0 $36,0004 $192,812 100 
1. Not including three people better off; 2. Minimum (-$15,000), Range $51,000; 
3. Not including two people better off; 4. Minimum (-$11,000), Range $47,000. 
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3.5  Other Associated Costs 
 
The last cost category examined is other expenses associated with MS, including the cost of 
alterations or upgrades of motor vehicles and houses, and transport costs. Table 25 is a summary 
of data for other associated costs paid by individuals.  The first aspect summarised is the cost 
associated with housing.  This figure is the total money spent by individuals with MS on altering 
their house to accommodate their MS needs, plus any costs people incurred in moving to another 
property because of their MS.  Twenty five per cent of respondents detailed costs in this area.  
The total cost for this group, adjusted from a cost over five years to a one-year period, was 
$32,159.  The next personal costs are for car alterations, which includes modification to hand 
controls and the purchase of modified vehicles.  Only eleven respondents (19 per cent) had car 
alteration costs, which resulted in a cost total of $14,400.  The travel costs incorporate petrol, 
taxis, bus fares and other expenses associated with the transport for MS related reasons, for 
example, doctor and hospital visits. Forty respondents (68 per cent) had travel expenses.  
Weekly costs were ascertained then multiplied over 12 months to a total annual figure of 
$55,056, which was 54 per cent of all other costs.  Overall, there is a total of $101,615 for all 
other costs paid for by the individual, with a mean of $1,722 per respondent. 
 
Table 25: Total Personal Direct Other Associated Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
House associated 
Car associated 
Transport  
15 
11 
40 
25 
19 
68 
545 
244 
933 
0 
0 
$520 
10,016 
3,600 
6,916 
32,159 
14,400 
55,056 
32 
14 
54 
Total / Summary 42 71 $1,722 $1,040 $11,316 $101,615 100 
 
 
Table 26 presents other costs paid for by government agencies.  The costs included home 
alterations paid for by hospitals and car suspensory loans.  Only eight per cent of respondents 
had such expenses, which totalled $8,114 per year. 
 
Table 26: Total Government Direct Other Associated Costs 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 $ % 
Home alterations  
Car suspensory loans 
3 
2 
5 
3 
$59 
$79 
$0 
$0 
$1,580 
$2,394 
$3,480 
$4,634 
43 
57 
Total / Summary 5 8 $138 $0 $2,394 $8,114 100 
 
 
The personal and government other associated costs are summarised in Table 27.  Personal 
direct costs dominate this analysis with $101,615 (93 per cent) of the total $109,729.  The mean 
other associated cost was $1,860 per respondent. 
 
Table 27: Total Other Associated Costs by Cost Bearer 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Personal other costs 
Government other costs 
42 
5 
71 
8 
$1,722 
$138 
$1,040 
$0 
$11,316 
$2,394 
$101,615 
$8,114 
93 
7 
Total / Summary 42 71 $1,860 $1,040 $11,316 $109,729 100 
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3.6  Summary 
 
Chapter 3 has examined the MS cost categories of medical costs, resource costs, income and 
employment costs and other associated costs.  For each cost category there was a presentation of 
indirect and direct costs, whether they were for the individuals with MS and for the government, 
and as a total for that category.  The following summarises the key results for each cost category: 
 
Medical Costs 
• Thirty-eight people with MS (64 per cent of respondents) experienced direct medical 
costs, which totalled $21,447 for 1999.  This was a combination of GP costs ($9,902) and 
prescription costs ($11,545).  The mean personal direct medical cost was $364 for 1999. 
• Thirty-five people with MS (59 per cent of respondents) incurred direct medical costs that 
were paid for by the government.  The total cost to government was $47,016 for 1999.  
The total was the sum of hospital treatment costs ($27,627), other health professional 
costs ($11,331) and prescription costs ($8,058).  The mean cost of each person in the 
study to the government was $797 per year. 
• The total of direct medical costs was $68,463, or $1,161 per person per year. 
• Twenty-six people experienced self directed alternative (indirect) medical costs.  These 
indirect costs were kept separate due to their elective nature.  Total indirect costs, which 
were incurred by individuals only, were $17,068, or $289 per respondent. 
• All medical costs, direct and indirect, paid for by cost bearers had a total of $85,531.  The 
mean was $1,450 per person for 1999. 
 
Resource Costs 
• Direct resource costs include people, services, equipment and maintenance of the 
resources and equipment used to assist living with MS. 
• The total personal direct resource costs was $55,334.  The total of  government direct 
resource costs was $118,206.  The total for both cost bearers was $173,540, with a mean 
direct resources cost of $2,941 per person. 
• Indirect resource costs apply to individuals only.  They are an estimate of the cost of 
informal assistance provided by family, friends and other volunteers.  The total informal 
assistance cost was $195,420, with a mean of $3,312 per person. 
 
Income and Employment Costs 
• Personal income can be lost through sick days, reduced work hours and loss of permanent 
employment.  
• Six people experienced sick days in 1999 due to MS at a cost of $30,770.  Ten people had 
to reduce work hours, with an income loss of $61,990 for 1999.  Sixteen people lost of 
potential income for 1999 of $275,278 due to having to stop work altogether because of 
MS.  The total potential income lost for the all individuals was $368,038.  The mean 
across all respondents was $6,238 per year. 
• Income losses were supplemented by the government via a range of benefit options. 
• Twenty-four people received financial support for government because of their inability 
to earn enough money to support themselves as a result of MS.  The total direct income 
costs for government were $239,336, with a mean of $4,056 per respondent. 
• Across individuals and government the total expense of lost work was $607,374.  For all 
59 respondents there was a mean of $10,294 per person for 1999. 
• Seventeen partners of people with MS experienced an income loss of $192,812. 
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Other Associated Costs 
• Other costs are alteration and upgrades of homes and vehicles, plus transport costs.  
• Personal other costs for 1999 equalled $101,615, while government other costs were 
minimal at $8,114.  Total other associated costs was $109, 729. The mean was $1,860. 
 
The next chapter brings together the costs categories summarised above.  The cost category 
totals are brought forward to give final totals on direct costs, indirect costs and all cost 
summaries, across cost bearers (personal and government) and cost categories. 
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Chapter 4 
Results: Total Costs and Summaries 
 
 
4.1  Introduction 
 
Chapter 4 summarises the results presented in Chapter 3.  The aim here is to present overall 
findings and establish the larger picture of total economic costs of RRMS. There will be a 
presentation of total costs by direct and indirect cost comparisons, personal and government cost 
comparisons, and all costs summaries.  By dividing the analysis into these sections, the aim is to 
present what are considered the key perspectives that will interest most observers of the findings.  
The chapter finishes with a comparison of costs for Group 1 and Group 2 to examine the 
changes in costs over time. 
 
 
4.2  Direct and Indirect Costs 
 
Individuals with MS only incur three of the four cost categories as direct costs.  These are 
medical costs, resource costs and other associated costs (See Table 28).  The most expensive 
personal direct cost category was other associated costs with a total of $101,615, which was 57 
per cent of total.  This incorporates costs associated with the living and transport arrangements, 
and home and vehicle alterations for people with MS.  Forty-two respondents (71 per cent) 
indicated that they had expenses in the other cost category.  The medical costs were the lesser 
cost category of all the personal direct costs at  $21,447.  The total personal direct costs was 
$178,395, which averages to $3,024 per respondents.  A very large proportion of respondents 
(92 per cent) indicated that they paid some form of direct cost associated with MS.  The 
maximum direct costs paid in one year by any one person was $15,599, which included direct 
resource costs of $8,683 and other associated costs of $6,916. 
 
Table 28: Total Personal Direct Costs by Cost Category 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Medical costs 
Resource costs 
Other associated costs 
38 
33 
42 
64 
56 
71 
$364 
$938 
$1,722 
$80 
$140 
$1,040 
$6,920 
$8,683 
$11,316 
$21,447 
$55,334 
$101,615 
12 
31 
57 
Total / Summary 54 92 $3,024 $1,596 $15,599 $178,395* 100 
*Does not equal sum of totals due to rounding. 
 
 
Table 29 presents the data for the direct costs that are paid for by government.   In this analysis 
all four cost categories are incorporated.  Medical costs, which was the lowest cost category for 
individuals, was the second lowest cost for the government.  However, the total government 
medical costs at $47,016 was twice the total of personal medical costs.  The highest government 
cost category was income costs.  These included benefits, ACC allowances and an assistance 
grant.  The total income costs was $239,336, which relates 41 per cent of respondents.  The 
average per respondent was $4,056.  Overall, the government experienced direct costs of 
$412,672 in 1999 for the 59 respondents (71 per cent actually acknowledged government related 
costs).  The mean cost to the government across all respondents was $6,994.  The maximum paid 
for any one individual was $38,763.  This was the same person that experienced the greatest 
personal direct costs.  Their government direct costs included costs of medical assistance 
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($2,408), resources and services paid for by the government ($17,909), plus government benefit 
assistance ($18,446). 
 
Table 29: Total Government Direct Costs by Cost Category 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Medical costs 
Resource costs 
Income costs 
Other associated costs 
35 
19 
24 
5 
59 
32 
41 
8 
$797 
$2,003 
$4,056 
$138 
$110 
$0 
$0 
$0 
$4,395 
$23,632 
$22,860 
$2,394 
$47,016 
$118,206 
$239,336 
$8,114 
11 
29 
58 
2 
Total / Summary 42 71 $6,994 $1,439 $38,763 $412,672 100 
 
 
Tables 30 and 31 summarise total direct costs.  Combining personal and government direct costs, 
Table 30 provides a total summary by the four costs categories.  The highest portion of costs 
were those related to income ($239,336; 40 per cent), which were government costs only, as 
individual income costs were indirect.  The next highest were resource costs ($173,540; 29 per 
cent), then other financial costs ($109,729; 19 per cent), and the last was medical costs ($68,463; 
12 per cent).  
 
Table 30: Total Direct Costs by Cost Category 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
Cost Cost % 
Medical costs 
Resource costs 
Income costs 
Other associated costs 
41 
39 
24 
42 
70 
66 
41 
71 
$1,161 
$2,941 
$4,056 
$1,860 
$601 
$520 
$0 
$1,040 
$8,540 
$29,772 
$22,860 
$11,316 
$68,463 
$173,540 
$239,336 
$109,729 
12 
29 
40 
19 
Total / Summary 54 92 $10,018 $5,428 $54,362 $591,068* 100 
*Different to total in Table 31 and 33 due to rounding. 
 
 
Table 31 presents total personal and government direct costs.  From the table it can be seen that 
92 per cent of respondents incurred personal direct costs and 71 per cent accrued direct costs for 
government.  However, total government direct costs ($412, 672; 70 per cent) outweighed total 
personal direct costs ($178, 395; 30 per cent).  Both Tables 30 and 31 show that the total figure 
for direct costs was $591,067.  This averaged to $10,018 for each respondent for the year 1999.  
The mean personal direct costs was $3,024 and mean government direct costs were $6,994. 
 
Table 31: Total Direct Costs by Cost Bearer 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Personal direct costs 
Government direct costs 
54 
42 
92 
71 
$3,024 
$6,994 
$1,596 
$1,439 
$15,599 
$38,763 
$178,395 
$412,672 
30 
70 
Total / Summary 54 92 $10,018 $5,428 $54,362 $591,067 100 
 
 
All indirect costs recorded in this research were attributed to the individuals with MS.  While 
there may also be indirect costs for the government, such as, less tax due to income loss, there 
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was not enough information available to determine actual values.  Further, the same applies for 
other potential indirect costs of partners’ lost income and loss of production for employers, these 
have not been considered in the final analysis. 
 
The names of the cost categories in the following table of indirect costs are different, in two 
cases, to the cost categories used in the direct cost summaries above, however they are related.  
The first category presented in Table 32 is “self-directed medical costs” (Cost Category: Medical 
Costs).  These include the alternative and self directed treatment costs incurred by individuals.  
They have been classed as indirect due to the elective nature of the cost.  This cost was the 
lowest of the indirect costs at ($17,068; 3 per cent).  The second category is “informal assistance 
costs” (Cost Category: Resource Costs).  Informal assistance costs are the values placed on the 
assistance provided by voluntary support, such as family members, friends and other voluntary 
workers.  This was the second highest indirect cost at $195,420, or 34 per cent of the total 
indirect costs.  This averages to $3,312 per respondent per year, although only 49 per cent of 
respondents had this form of cost.  The highest indirect cost to individuals was income and 
employment costs.  This incorporates income lost through sick days, reduced hours and 
unemployment because of MS.  Forty-seven per cent of people recorded losing such income.  
The total potential income lost for the group in 1999 was $368,038, or 63 per cent of total 
indirect costs.  The maximum indirect costs  for any one individual was $108,428.  This was the 
ex-self-employed person who had high income costs.  The next highest individual indirect totals 
were $48,600 and $37,160. 
 
Table 32: Total Indirect Costs by Cost Category 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Self-directed medical costs 
Informal assistance costs 
Income costs 
26 
29 
281 
44 
49 
47 
$289 
$3,312 
$6,238 
$0 
$0 
$0 
$5,400 
$29,120 
$90,2282 
$17,068 
$195,420 
$368,038 
3 
34 
63 
Total / Summary 443 75 $9,839 $2,270 $108,4284 $580,526 100 
1. Not including two people better off; 2. Minimum (-$8,000), Range $98,228. 
3. Not including two people better off; 4. Minimum -$3,320, Range $111,748 
 
 
Table 33 shows the difference between the direct and indirect categories, with a final total for all 
costs. This is the first time the total cost of MS is presented.  There was no notable difference in 
the total figures of each, with an almost 50/50 split of the overall total.  Over 90 per cent of 
respondents experienced direct costs, while 75 per cent experienced indirect costs.  There was a 
total cost of $1,171,593 for the 59 people in the study for 1999, with a mean of $19,857.   
 
Table 33: Total Costs by Type (Direct / Indirect) 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Total direct costs 
Total indirect costs 
54 
441 
92 
75 
$10,018 
$9,839 
$5,428 
$2,720 
$54,362 
$108,4282 
$591,067 
$580,526 
50.5
49.5
Total / Summary 55 93 $19,857 $10,705 $162,790 $1,171,593 100 
1. Not including two people better off; 2. Minimum (-$3,320), Range $111,748.  
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4.3  All Costs 
 
In this section the economic costs of MS are presented as a variety of final summaries.  There is 
no distinction of direct and indirect costs.  All costs are presented  by comparing cost bearers and 
cost categories.  The first section is an analysis of the features of the highest and most frequent 
separate costs. 
 
Table 34 is a breakdown of all costs that are components of cost categories outlined in this 
report.  The separate components are sorted from highest cost to lowest cost.  Each cost is 
classified in two ways: as individual (I) or government (G), and as direct (D) or indirect (I). The 
shaded areas are the details of the highest ten costs.  The highest cost was the individual indirect 
cost of “potential annual income lost”.  This cost accounted for 23 per cent of the overall cost 
total.  The second highest cost was the highest direct cost of “benefit assistance” paid by the 
government.  This cost’s value was 19 per cent of all costs.  The highest individual direct cost 
was fifth, that is, “resource costs”, which was 5 per cent of total costs.  
 
Table 34: Rank Order of All Costs – Due to MS 
 
Response Total Cost Description 
No. % 
Mean 
(n=59) 
Max.  
Cost % 
Potential annual income lost (I/I) 16 32 $4,666 $90,228 $275,278 23 
Benefit assistance (G/D) 21 36 $3,788 $22,860 $223,475 19 
Family assistance (I/I) 25 42 $3,054 $29,120 $180,180 15 
Resources (G/D) 19 32 $2,003 $23,632 $118,206 10 
Reduced working hours (I/I) 10 17 $1,051 $12,600 $61,990 5 
Resources (I/D) 33 56 $938 $8,683 $55,334 5 
Transport (I/D) 40 68 $933 $6,916 $55,056 5 
House associated (I/D) 15 25 $545 $10,016 $32,159 3 
Working days lost (I/I) 6 10 $521 $18,000 $30,770 3 
Hospital treatment (G/D) 22 37 $468 $4,395 $27,627 2 
Other informal assistance (I/I) 7 12 $258 $8,400 $15,240 1 
Self-directed medication (I/I) 25 42 $246 $5,400 $14,518 1 
Car associated (I/D) 11 19 $244 $3,600 $14,400 1 
Prescriptions (I/D) 29 49 $196 $5,000 $11,545 1 
Other health professionals (G/D) 15 25 $192 $3,856 $11,331 1 
GP visits (I/D) 34 58 $168 $1,920 $9,902 1 
ACC (G/D) 7 12 $167 $8,834 $9,866 1 
Prescriptions (G/D) 21 36 $137 $992 $8,058 1 
Grants (G/D) 1 2 $101 $5,995 $5,995 1 
Car suspensory loans (G/D) 2 3 $79 $2,394 $4,634 0 
Home alterations paid HFA (G/D) 3 5 $59 $1,580 $3,480 0 
Alternative treatments (I/I) 7 12 $43 $650 $2,550 0 
Total / Summary 55 93 $19,857 $162,790 $1,171,593 100 
 
 
Table 35 is a portion of the information presented in the above table.  It presents the ten most 
frequently reported costs.  The same classifications applied in Table 34 are used here.  The most 
common was transport costs, with 68 per cent of respondents having some form of expense in 
this area.  The next three most common costs were GP costs (58 per cent), resource costs (56 per 
cent) and prescription costs (49 per cent).  The top four most common costs were all personal 
direct costs.   The most frequent government cost was hospital treatment costs, which was 
seventh on the list, with 37 per cent of participants generating expenses in this area. 
 31
Table 35: Ten Most Frequently Reported Costs 
 
Response Total Cost Description 
No. % 
Mean 
(n=59) 
Max.  
Cost % 
Transport (I/D) 40 68 $933 $6,916 $55,056 5 
GP visits (I/D) 34 58 $168 $1,920 $9,902 1 
Resources (I/D) 33 56 $938 $8,683 $55,334 5 
Prescriptions (I/D) 29 49 $196 $5,000 $11,545 1 
Family assistance (I/I) 25 42 $3,054 $29,120 $180,180 15 
Self-directed medication (I/I) 25 42 $246 $5,400 $14,518 1 
Hospital treatment (G/D) 22 37 $468 $4,395 $27,627 2 
Benefit assistance (G/D) 21 36 $3,788 $22,860 $223,475 19 
Prescriptions  (G/D) 21 36 $137 $992 $8,058 1 
Resources (G/D) 19 32 $2,003 $23,632 $118,206 10 
 
 
Tables 36 and 37 show the breakdowns of total cost categories as they stood for individuals and 
government, respectively.  The highest personal and government costs were income related.  
Personal income costs were $368,038 and government income costs were $239,336.  Second 
highest were resource costs with personal resource costs at $250,754 and government resource 
costs at $118,206.  They also differed slightly in percentage of the total for each cost bearer, that 
is, personal income costs were 49 per cent of the personal total, while government income costs 
were 58 per cent of the government total.  Resource cost differences were personal costs, 33 per 
cent, and government costs, 29 per cent.  There was a difference in the order and percentages of 
the lower two cost categories, which was, medical costs and other financial costs.   Personal 
medical costs were $38,514, or 5 per cent of all personal costs.  Government medical costs were 
$47,016, or 11 per cent of all government costs.  This order reversed for other financial costs.  
Personal other associated costs totalled $101,615, or 13 per cent of all personal costs, while 
government resource costs totalled $8,114, or 2 per cent of all government costs.  For resource, 
medical and other costs the expense to the person with MS is greater than that to the government 
 
Table 36: Total Personal Costs by Cost Category 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Medical costs 
Resource costs 
Income costs 
Other associated costs 
46 
42 
281 
42 
78 
71 
47 
71 
$653 
$4,250 
$6,238 
$1,722 
$256 
$1,165 
$0 
$1,040 
$7,440 
$29,302 
$90,2282 
$11,316 
$38,514 
$250,754 
$368,038 
$101,615 
5 
33 
49 
13 
Total / Summary 553 93 $12,863 $5,943 $124,0274 $758,921 100 
1. Not including two people better off; 2. Minimum (-$8,000), Range $98,228;  
3. Not including one person better off; 4. Minimum (-$489); Range $124,516 
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Table 37: Total Government Costs by Cost Category10 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Medical costs 
Resource costs 
Income costs 
Other associated costs 
35 
19 
24 
5 
59 
32 
41 
8 
$797 
$2,003 
$4,056 
$138 
$110 
$0 
$0 
$0 
$4,395 
$23,632 
$22,860 
$2,394 
$47,016 
$118,206 
$239,336 
$8,114 
11 
29 
58 
2 
Total / Summary 42 71 $6,994 $1,439 $38,763 $412,672 100 
 
 
When the cost bearers were compared the difference between personal costs and government 
costs became more noticeable.  Table 38 shows that personal costs outweigh government costs 
by 65 per cent to 35 per cent of the overall total cost of $1,171,593.  This difference was 
reflected further in the mean cost of MS per person, which was $19,857.  The cost bearer means 
were personal costs of $12,863 and government costs of $6,994.  There was also a 22 per cent 
difference in the number of people that experienced costs themselves (93 per cent) as opposed to 
receiving some form of government assistance (71 per cent).  These statistics indicate that 
government covered around one third of all costs associated with MS, and just over one fifth of 
people did not receive government assistance. 
 
Table 38: Total Costs by Cost Bearer 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median
(n=59) 
Max. 
 Cost % 
Total personal costs 
Total government costs 
551 
42 
93 
71 
$12,863 
$6,994 
$5,943 
$1,439 
$124,0272 
$38,763 
$758,921 
$412,672 
65 
35 
Total / Summary 55 93 $19,857 $10,705 $162,790 $1,171,593 100 
1. Not including one person better off; 2. Minimum (-$489), Range $124,516. 
 
 
Table 39 represents the overall analysis of all costs by cost category.  This analysis brings all 
costs together but does not present any new findings. This information does, however, enable a 
summary of the overall economic situation to be highlighted.  The total costs that the 59 research 
subjects could attribute to the one-year period of 1999 was $1,171,593.  Ninety three per cent of 
respondents experienced or generated some form of cost associated with MS. The highest cost 
category was income costs with $607,374 (53 per cent of all costs) for the year.  The lowest cost 
category was medical costs at $85,531 (7 per cent of total costs).  The most common cost 
category was medical costs with 81 per cent of respondents recording some form of expense.  
The highest cost associated with any one person with MS for the one-year period was $162,790.  
This respondent had $108,428 in indirect costs of income lost and informal assistance, with 
direct costs of $54,362. The indirect figure consists of informal assistance costs from friends, 
family and volunteers ($18,200) with an annual income loss ($90,228).  The direct cost figure 
consisted of individual medical costs ($2,408), government resource costs ($17,909), individual 
resource costs ($8,683), government assistance ($18,446) and individual other financial costs 
($6,916).  The next highest maximum costs for individuals with MS were $88,844 and $71,219.  
The highest contributing category for both these individuals was resource costs of $45,972 and 
$47,724, respectively. 
                                                
10 Table 37 representing Total Government Costs presents the same information as Total Government Direct Costs 
(Table 29).  There was no change in the government cost totals as there were no indirect costs to be incorporated 
into the final total. 
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Table 39: Total Costs by Cost Category 
 
Responses Total Cost Description 
No. % 
Mean 
(n=59) 
Median 
(n=59) 
Max. 
 Cost % 
Medical costs 
Resource costs 
Income costs 
Other assoc. costs 
48 
44 
351 
42 
81 
75 
61 
71 
$1,450 
$6,253 
$10,294 
$1,860 
$731 
$1,560 
$4,948 
$1,040 
$10,165 
$47,724 
$108,6742 
$11,316 
$85,531 
$368,960 
$607,374 
$109,729 
7 
31 
53 
9 
Total / Summary 55 93 $19,857 $10,705 $162,790 $1,171,593 100 
1. Not including one person better off; 2. Minimum (-$2,834), Range $111,508. 
 
 
4.4  Comparison of Costs Over Time 
 
A main objective of the research was to ascertain whether there was a positive relationship 
between costs of MS and how long a person had experienced the condition.  The hypothesis was 
that costs associated with MS would increase over time.  To test this hypothesis two groups were 
identified within the research population.  The groups were based on when respondents had been 
first diagnosed with MS.  Group 1 consisted of 24 respondents who were diagnosed with MS 
from 1984 to 1989, inclusive.  Group 2 consists of 35 respondents who were diagnosed with MS 
from 1990 to 1995, inclusive (See Table 1, pg. 5).  If a positive hypothesis between time with 
MS and cost was to be confirmed then Group 1 was expected to have higher costs than Group 2.  
This research does not fully support this hypothesis. 
 
Table 40 compares the means and proportion percentages for Group 1 and Group 2 across the 
range of primary cost totals.  The higher means and proportions are shaded.  The other columns 
show the summary of means and proportions for the total research population.  These will not be 
discussed, though they do offer a reference point for each group.   
 
For the 24 respondents with MS in Group 1 the mean cost for all aspects of MS for 1999 was 
$17,660.  For the 35 respondents with MS in Group 2, the mean cost for all aspects of MS for 
1999 was $21,364.  In only six cost totals out of a possible 21 did Group 1 have greater mean 
costs than Group 2.   These were: Government Direct Resource Costs; Personal Indirect 
Resource Costs (Informal Assistance); Total Resource Costs; Government Income Costs; 
Government Direct Other Costs; and Total (and Direct) Government Costs.  Further, there were 
two other costs for Group 1 where the proportion was higher than that for Group 2.  These 
additional two totals were: Government Medical Costs and Total Direct Costs.  These figures 
indicate that people in the study that had MS longer were incurring higher government costs for 
the use of  services and resources, benefits and other associated costs.  They also had a higher 
value for assistance from family and friends.  This suggests that people who have had MS for 
longer require more assistance than people that have had MS for a shorter time.  They also cost 
more to the government than people who had MS for a shorter period.  They do not, however, 
have the greater overall cost for living with MS. 
 
The remaining costs were all greater for people in Group 2 who had MS for a shorter time. A 
synthesis of the differences indicate a number of aspects about Group 2.  They personally paid 
greater amounts in medical costs.  The medical costs were also greater across direct and indirect 
means.  The higher medical costs may indicate that people more recently diagnosed with MS 
were more likely to try a range of medications and treatments.  They also experienced greater 
costs to themselves in resources and services used and other costs than those that had lived with 
MS longer.  Group 2 respondents also encountered far higher income costs through lost work.  
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They paid more in personal direct costs than Group 1 respondents.  They also experienced 
greater indirect personal costs.   
 
As mentioned, Group 2 had a higher mean total cost of $21,364, while Group 1 had a mean total 
cost of $17,660.  The difference was $3,704.  The proportion differences for personal and 
government total costs across Group 1 and Group 2 are also worth noting.  For Group 1 the ratio 
was personal, 57 per cent; government, 43 per cent.  For Group 2 the ratio was personal, 69 per 
cent; government, 31 per cent.  This indicates a heavier cost burden for a person more recently 
diagnosed with MS.  Respondents who had MS for a shorter period not only incurred higher 
costs across a range of expenses, but they also incurred the greater total costs for themselves, and 
for the final total of MS related costs.  
 
 Table 40: Difference in Cost Over Time 
 
 Group 1 (n=24) Group 2 (n=35) Total (n=59) 
Cost Summaries Mean % Mean % Mean % 
Personal Direct Medical Costs $281 25 $420 25 $364 25 
Government Direct Medical Costs $711 64 $856 51 $797 55 
Personal Indirect Medical Costs $124 11 $402 24 $289 20 
Total Medical Costs $1,115 100 $1,679 100 $1,450 100 
Personal Direct Resource Costs $508 6 $1,233 24 $938 15 
Government Direct Resource Costs $2,672 34 $1,545 30 $2,003 32 
Personal Indirect Resource Costs $4,774 60 $2,309 46 $3,312 53 
Total Resource Costs $7,955 100 $5,087 100 $6,253 100 
Personal Indirect Income Costs $2,958 42 $8,486 68 $6,238 61 
Government Direct Income Cost $4,066 58 $4,050 32 $4,056 39 
Total Income Costs $7,024 100 $12,536 100 $10,294 100 
Personal Direct Other Costs $1,421 91 $1,929 94 $1,722 93 
Government Direct Other Costs $145 9 $132 6 $138 7 
Total Other Associated Costs $1,566 100 $2,061 100 $1,860 100 
Direct Costs by Cost Bearer:     
Total Personal Direct Costs $2,210 23 $3,582 35 $3,024 30 
Total Government Direct Costs $7,594 77 $6,584 65 $6,994 70 
TOTAL DIRECT COSTS $9,803 100 $10,165 100 $10,018 100 
All Costs by Category:     
Total Medical Costs $1,115 6 $1,679 8 $1,450 7 
Total Resource Costs $7,955 45 $5,087 24 $6,253 31 
Total Income Costs $7,024 40 $12,536 59 $10,294 53 
Total Other Associated Costs $1,566 9 $2,061 9 $1,860 9 
All Costs - Indirect/Direct Costs:     
Total Indirect Costs $7,857 44 $11,199 52 $9,839 49.5 
Total Direct Costs $9,803 56 $10,165 48 $10,018 50.5 
All Costs by Cost Bearer:     
Total Personal Costs $10,066 57 $14,781 69 $12,863 65 
Total Government (Direct) Costs $7,594 43 $6,584 31 $6,994 35 
TOTAL COSTS $17,660 100 $21,36411 100 $19,857 100 
                                                
11 Group 2 has one case with exceptionally higher Income and Total Costs.  Analysis with this case removed does 
change the mean comparisons between Group 1 and Group 2 and produces a more even Total Cost comparison, 
though the general picture remains constant.  The cost areas where prominence between the groups changes are 
Total Direct Costs (Group 1 $9,803; Group 2 $8,856) and Total Costs (Group 1 $17,660; Group 2 $17,204).  It also 
enhances the prominence in Resource and Government Costs for Group 1 in most cost areas. 
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4.5  Summary 
 
This chapter reports the overall costs of MS.  The analysis provided breakdowns of total costs by 
cost bearer (personal and government) and cost category (medical, resources, income and other 
cost) perspectives within direct cost, indirect cost, and all cost totals.  There was also a 
comparison of costs over time using two diagnostic groups.  They were Group 1 (24 respondents 
diagnosed from 1984 to 1989, inclusive) and Group 2 (35 respondents diagnosed from 1990 to 
1995, inclusive).  The key findings from these analyses are as follows: 
 
Direct and Indirect Cost Summary 
• The highest personal direct cost was other associated costs at $55,334, or 57 per cent of 
total personal direct costs of $178,395. 
• The highest government direct cost was income costs, mainly consisting of benefits, at 
$239,336, or 58 per cent of total government direct costs of $412,672. 
• Income costs were also the greatest overall direct cost for both personal and government, 
being 40 per cent of total direct costs of $591,068.  Second highest was resource costs at 
29 per cent.  Direct other costs were 19 per cent and direct medical costs were 12 per 
cent. 
• Government bore $412,672, or 70 per cent, of total direct costs. 
• Personal income costs were the highest indirect cost at 63 per cent; Informal assistance 
costs were 34 per cent and self-directed medical costs were only 3 per cent of all indirect 
costs. 
• Direct costs were $591,418 (50.5 per cent) and indirect costs were $580,526 (49.5 per 
cent). 
 
All Cost Summary 
• The three highest separate costs were: 1. Potential annual income lost ($275,278, 23 per 
cent); 2. Benefit assistance ($223,475, 19 per cent); and, 3. Family assistance ($180,180; 
15 per cent).  Only benefit assistance was a direct cost. 
• The three most frequently reported costs were: 1. Transport costs (40 per cent of 
respondents); 2. GP costs (34 per cent of respondents); and, 3. Personal resource costs 
(33 per cent of respondents).  The top six most common costs were incurred by 
individuals. 
• The highest costs encountered by people with MS were income costs of $368,038, or 49 
per cent of total personal costs.   Second highest was resource costs of $250,754, or 33 
per cent.  Other costs were 13 per cent and medical costs were five per cent. 
• Total government costs are the same as total government direct costs, as there were no 
government indirect costs. 
• Personal costs were for 65 per cent of all costs and government accounted for 35 per 
cent. 
• Ninety-three per cent of respondents paid MS related costs, while 71 per cent had 
government assistance for some MS costs.  
• The highest overall cost was income costs of $607,374, or 53 per cent of all costs.  Next 
were: resource costs, 31 per cent; other costs, nine per cent; and, medical costs, seven per 
cent.  
• The totals cost of MS to the 59 research respondents was $1,171,593.  The average costs 
of MS per person was $19,857. 
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Group 1 and Group 2 Summary 
• People that had MS for a longer duration cost the government more in all aspects than 
people who had it for a shorter period. 
• The people that had MS for a shorter time incurred greater expenses for medical costs, 
greater personal expense for resources, services and other costs.  They had a greater loss 
of potential income for the year of study and cost the government more in benefit 
assistance.  Overall, they paid more MS related costs themselves, had proportionally less 
assistance from government and had greater total MS related costs than people who had 
MS longer.  They also spent more on alternative treatment options. 
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Chapter 5  
Discussion and Conclusion 
 
 
5.1  Discussion 
 
The research method used here was a prevalence approach, bottom-up cost of illness study.  This 
means that the study of costs was for a given year, and based on the total costs for a defined sub-
population with MS.  In this research the study year was 1999 and the sub-population was 
people with relapsing-remitting multiple sclerosis, diagnosed from 1984 to 1995 inclusive12 and 
living in the Canterbury / Westland area.  
 
This study found that the economic costs of RRMS per individual were relatively high at 
$19,857 per person for 1999, with a total for all 59 respondents of $1,171,593.   There was 
almost a 50/50 split in the total between direct and indirect costs. The proportions of total costs 
by cost bearer were personal, 65 per cent, and government, 35 per cent.  Ninety-three per cent13 
of respondents incurred MS related costs, while 71 per cent had government assistance for some 
MS costs, which was a 22 per cent difference.  Therefore, government covered about one third 
of all costs associated with MS and just over one in five respondents were not receiving any 
form of government assistance.  Further, the costs of MS were not greater for people that had the 
condition longer (10+ years).  People who had MS for a shorter time (0-9 years) incurred the 
greater level of costs, most of which were paid for by themselves.  People with MS longer 
required more informal assistance and had greater government costs.  
 
There are three notable reasons for underestimated costs in this study.  Firstly, the findings are 
limited by the size of the MS sub-group (relapsing-remitting MS, in the Canterbury / Westland 
region, matching diagnostic criteria from 1984 to 1995 inclusive), which realistically is a “less 
expensive” representation of people with MS.  Secondly, there is a lack of details regarding 
some aspects of the indirect economic costs of MS.  The final totals do not include partners’ loss 
of income, loss of tax revenue for the government, cost of lost productivity for employers, and 
flow-on cost effects to family and friends that care for a person with MS.  Partners’ loss of 
income was $192,812 (See Table 24, p.23), though was not included in the final total due the 
inability of many respondents to provide details of their partner’s earnings.  Another cost not 
included in the final total was loss of tax revenue.  Other international studies include lost tax 
revenue in their overall economic assessments (Holmes, 1995).  While not purposely isolated in 
the research, there is a possibility that a tentative figure for tax revenue lost could be based on 
the potential income lost by individuals.  A suggested calculation works as follows: Total 
Personal Income Costs of $368,038 divided by the number of people with income costs (30 
people) gives an average income of $12,268.  The tax on this amount at 19.5 per cent is $2,392 
per person.  For the 30 people the estimated tax loss is $71,767.  This figure would be higher if 
tax from partners’ lost income was also considered.  Thirdly, the intangible costs that stem from 
the psychological, stress-related impacts of MS on the person and their carers are also not 
included.  As a result of these three factors, the findings presented are a conservative 
representation of MS costs for the Canterbury / Westland for 199914.  In the absence of New 
Zealand information, however, this study provides valuable information such as identifying the 
types of costs of MS in this country.  The results are, therefore, valuable and useful despite 
having limitations.  There is scope for future research to improve on the measures adopted here. 
 
                                                
12 With there being an average of eight years since matching diagnostic criteria. 
13 The remaining seven percent provided no cost details. 
14 Also attributable was the systematic method of under-estimating costs during the information gathering stage. 
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The findings also suggest that living with MS is the cause of financial limitation for many 
people, for example: Fifty-nine per cent of respondents had partners with income.  This left 41 
per cent of respondents reliant on single incomes, whether they were single, had partners and/or 
families.  The average annual income of the respondents was $18,755.  The average personal 
direct costs (MS “cash” costs, except alternative treatments) was $3,024.  This means that for 
two out of five respondents potentially 15 per cent of their income was committed to MS costs.  
This is a sizeable proportion of income committed to MS related expenses for people already in 
an economically deprived group.  If indirect costs are also included then the proportion of costs 
to income will be considerably higher. 
 
This study identifies that the cost of MS was greater for people more recently matching RRMS 
diagnostic criteria, which was not the expectation before the research began.  There was no 
particular aspect that identified why this has occurred.  It is a reasonable assumption, however, 
that during an initial period of acceptance, transition and adjustment people are likely to 
experience changes in their employment arrangements and try different methods of medication 
(including alternative options15) to manage their condition, which in combination have a notable 
personal financial impact.  People that have had MS for longer are likely to be more settled in 
living with their condition and have had time to understand their circumstances, have found what 
works best and obtained their financial and service entitlements from government sources.  They 
are also more likely to be older and to have retired from work (either forced or natural), and may 
have become accustomed to financial limitations that come with the MS condition.  
 
There is a further reflection of the financial impacts on newly diagnosed people with MS that 
connects to the decisions they make surrounding the treatment of their condition. All 
respondents, in their search for methods to control and alleviate their conditions spent 44 per 
cent of personal medical costs, or 20 per cent of all medical costs, on alternative options.  While 
all medical costs were only seven per cent and the alternative options just over one per cent of all 
costs, it was significant that forty-four per cent of respondents had spent money on alternative 
treatments and medication in 1999.  The level of spending on alternative treatment suggests that 
there is a need for a review of policies regarding the education of people to ensure they are 
making informed choices about their treatment.  Further research on the types of alternative 
options and perceptions of and reasons for use would be useful. 
 
The results of this study are reasonably in line with those in developed countries, such as the 
United States, Canada, the United Kingdom, Norway and Sweden.  A brief comparison of 
findings from a range of international studies is presented in Table 41. The most consistent 
aspect across the national studies over different years is that the indirect costs of lost earnings are 
commonly the highest costs.  The Canterbury / Westland study resembles these and had lost 
earnings and the cost of benefit assistance as the highest costs.  This study has a difference in the 
ratio of direct to indirect costs, while other nations have indirect costs as a much greater 
proportion of all costs than direct costs.  If the reasons for underestimation, highlighted earlier, 
are taken into account then the ratio between direct and indirect costs in this study would likely 
closer represent those of other nations.  It would also make the estimated annual cost to New 
Zealand greater than the NZ$69.5 million that is shown. 
 
The table also outlines the national cost of MS for each study and the average cost per person, 
where possible.  The figures are not conducive to an accurate comparable analysis due to 
differing time periods and currencies.  A more accurate comparison would consider the 
individual fluctuations of national inflation rates and exchange rates to one fixed currency (i.e. 
the United States Dollar) for each study since their completion.  This was not in the scope of this 
particular research.  The results confirm that the national and individual costs of MS across 
                                                
15 Most recent diagnosed people spent more on alternatives than those that had been diagnosed for a longer time. 
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various countries are significant, and in some cases, the costs are increasing. This conservative 
New Zealand regional study shows that the cost of MS are high, but evidence from other 
countries, plus understandings of non-included indirect costs, suggests that they are likely to be 
higher.  It is likely that costs would be confirmed as greater in a comprehensive national study. 
 
Table 41: Comparison with International Studies of MS Costs16 
Study Country & 
Reference 
Study  
Year 
 
Annual 
National 
Cost 
Cost Per 
Person 
Direct / 
Indirect 
Ratio 
Highest Cost 
Category 
New Zealand 
(This report, 2001) 
1999 NZ$69.5 
million (est.) 
NZ$19,857 D - 50.5 % 
I - 49.5 % 
Lost 
Earnings, and 
Benefits 
Canada 
(Burden of Illness 
Study Group, 
1998) 
1995  CD$24,41517 D –19 % 
I – 81 % 
Lost 
Activity/Leis
ure Time and 
Productivity 
Canada 
(Asche et al., 
1997) 
1994 CD$502.3 
million 
CD$18,673 D – 37.5 % 
I – 62.5 % 
Lost  
Productivity 
Sweden (2) 
(Henriksson and 
Jonsson, 1998) 
1994 SEK 1,876 
million 
 D – 20 % 
I – 80 % 
Lost  
Earnings 
United Kingdom 
(Holmes et al., 
1995) 
1993 - 
1994 
GB£1.2 
billion 
GP£13,75018   Lost 
Earnings 
United States 
(Whetten-
Goldstein et al., 
1996) 
1994 US$9.7 
billion 
US$35,000  Lost 
Earnings, and 
Informal 
Care 
England and 
Wales (2) 
(Wood, 1994) 
1993/4 GB£273.2 
million 
 D – 8 % 
I – 92 % 
 
United States 
(Veterans) 
(Bourdette et al., 
1993) 
1988 - 
1990 
 US$35,000  Benefits and 
Homecare 
Sweden (1) 
(Jonsson, 1995) 
1991 SEK 1,525 
million (US$ 
216 million) 
SEK 190,625 
(US$ 27,000) 
 
D – 29 % 
I – 71 % 
Lost 
Earnings 
Norway 
(Midgard et al., 
1996) 
1991 NOK 34.4 
million 
 D – 17 % 
I – 83 % 
Lost  
Earnings 
England and 
Wales (1) 
(O’Brien, 1987) 
1986/7 GB£125.4  D – 15 % 
I – 85 % 
Lost 
Earnings 
 
 
                                                
16  For a recent and critical review of major MS costs of illness studies in literature see Grudzinski et al. (1999). 
17 Average of three MS groups of mild, moderate and severe MS (Burden of Illness Study Group, 1998).  
18 Average of three MS types over state burden and individual burden (Holmes et al., 1995). 
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In addition, it must be re-emphasised that this study has only included people who have 
presented with relapsing-remitting MS.  This is not the case with all of the other studies in Table 
41.  Primary progressive MS produces a gradually accumulating disability and would be 
expected to result in quite a different pattern of economic effects.  Inclusion of this category of 
MS would be expected to substantially increase the annual national cost. 
 
Beyond the parallels to international results, the findings of this New Zealand regional study 
opens discussion and raises questions about the way MS is affecting the individual and the wider 
society.  A better overall understanding of individuals’ emotional, physical and financial needs, 
when facing a life with a debilitating condition like MS, would assist in government and the 
wider community’s responses to the needs of people in less fortunate circumstances.  The fact 
that the greatest costs of MS is the personal expense of lost income, which in many cases would 
result in considerable changes in lifestyle, tend to be overlooked by many who see benefits and 
health funding as primary social costs.  Their may also be a need for government policy makers 
and health funding providers to consider that paying for treatment that enables longer periods of 
financial independence and normality of life, which may have greater longer term economic and 
social benefits than funding on an as-needed, deterioration basis.   
 
 
5.2  Conclusion 
The cost to people in the Canterbury / Westland region with the relapsing-remitting MS, the 
people that they live with and the New Zealand Government is relatively high.  The figures 
presented in this report offer a conservative picture of MS in comparison to other nations’ 
studies, but there is no doubt that there are significant financial consequences for this country.  
These findings also show that the costs of relapsing-remitting MS do not necessarily increase the 
longer a person has the condition within the timeframe studied, that is, with an average of eight 
years from diagnosis.  In fact, these results indicate that people with MS longer incur less overall 
costs, yet they do accumulate higher cost for government.  Whereas, people with MS for shorter 
periods have greater overall cost, and noticeably higher personal costs.  The economic impact of 
MS appears more relevant for single or low-income families of people recently diagnosed with 
MS.  Views surrounding what are the real costs will differ depending on the association a person 
makes to the importance of indirect costs, such as, loss of income, voluntary assistance and 
alternative medical expenses. The reality is, however, that for a person or family on a single or 
low income the proportion of costs associated with MS will be financially detrimental, whatever 
the accepted cost structure.  This indicates that there may be more of a need to alleviate 
symptoms as early in the development of MS as possible.  By keeping people well enough to 
work reduces lost income effects for the individuals, their partners and their families, 
particularly at the earlier stages, and will push back the reliance on government and informal 
carers at the later stages.  It would seem that there would also be an alleviation of the “intangible 
costs” of psychological impacts and related stresses associated with the tangible financial 
consequences of a diagnosis of MS.  Further, the costs and flow-on impacts would be greater for 
all concerned when considering more advanced MS than relapsing-remitting. 
 
The findings and their supporting discussions are not attempts to influence discussion or policy 
surrounding any particular forms of treatment of MS in New Zealand.  An aim of this research 
was to understand the costs associated with MS in New Zealand.  It is accepted that this research 
is a precursor to a more efficient economic evaluation, that is, a comprehensive national study.  
It does, however, establish a base from which initial estimations of the cost of MS over a 
lifetime19, the national cost of MS20, categories of costs associated with MS and the proportions 
                                                
19 If the average time with MS is 25 years, and if the average cost of $19,857 remained constant, then the total cost 
over a lifetime equals $496,425 (personal = $321,575; government = $174,850). 
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of costs can be made in a New Zealand context.  Apart from these, the quantifying of costs 
associated with MS at this level, at least, provides a clearer picture than there was before.  
Further, the information gathered has other values in highlighting and informing other topical 
issues surrounding MS, such as the use of alternative treatments and the impacts of intangible 
costs.  There is considerable scope for greater investigation of the economic and social costs of 
MS in New Zealand.  This research sets the stage for beginning to enhance our understandings 
of the range of these economic and social consequences.  The obvious contending topics for 
further investigation are summarised as follows: 
 
• Alternative treatment use: The use of alternative treatments by people who have MS 
appears significant, (44 per cent).  Whether this is higher than in other chronic illnesses is 
not known.  Neither is it known whether the level of usage could be related to cognitive 
changes, which can affect judgement, or to a lack of knowledge regarding available 
orthodox treatments. This could be a field for further investigation.  Increased education 
for people with MS regarding orthodox symptom management may be helpful as well as 
additional information resources for General Practitioners. 
• In-depth national study of the costs of MS: Undertake a comprehensive national study of 
MS.  Ensure there is wider consideration of all stages of MS, representative of all people 
with MS in New Zealand and unrestricted by where and when they were diagnosed; and 
incorporate the indirect costs of loss of tax revenue, partner and family member income 
losses and loss of industry productivity. 
• Study of intangible costs: To consider and begin to understand the greater ‘social’ and 
‘emotional’ consequences of MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                          
20 An estimate from MS Society sources stated that there were 3-4,000 people with MS in New Zealand.  For an 
average of 3,500, the total cost of MS in New Zealand in 1999 would have been around $69.5 million (personal = 
$45 million; government = $24.5 million). 
 42
 
 43
References 
 
 
Asche, C.V., Ho, E., Chan, B., and Coyte, P.C. (1997) Economic consequences of multiple 
sclerosis for Canadians.  Acta Neurologica Scandinavica, 95(5):268-74. 
 
Bourdette, D.N., Prochazlea, A.V., Mitchell, W., Licari, P., and Burks, J. (1993) Health care 
costs of veterans with multiple sclerosis.  Archives of Physical Medicine and 
Rehabilitation, 74(1):26-31. 
 
Grudzinski, A.N., Hakim, Z., Cox, E.R., and Bootman, J.L.  (1999)  The economics of multiple 
sclerosis: distribution of costs and relationship to disease severity.  Pharmacoeconomics, 
15 (3): 229-240. 
 
Henriksson, F., and Jonsson, B. (1998) The economic cost of multiple sclerosis in Sweden in 
1994.  Pharmacoeconomics, 13: 597-606. 
 
Holmes, J., Madgwick, T., and Bates, D. (1995) The cost of multiple sclerosis.  British Journal 
of Medical Economics, 8:181-193. 
 
Inman, R.P. (1984) Disability indices, the economic costs of illness, and social insurance: the 
case of multiple sclerosis.  Acta Neurologica Scandinavica Supplementum, 101:46-55. 
 
Jonsson, B. (1995) The economic costs of multiple sclerosis in Sweden.  EFI Research Paper 
6551.  Stockholm School of Economics: Stockholm. 
 
Lissovoy, G., and de Lazarus, S.S. (1996) The economic cost of migraine: present state of 
knowledge. Neurology, 44(4):856-862. 
 
Midgard, R., Riise, T., and Nyland, H. (1996) Impairment, disability and handicap in multiple 
sclerosis. A cross sectional study in More and Romsdal County, Norway.   J Neurol. 243: 
337-344. 
 
MS Forum (1995) Economic evaluation and consequences of multiple sclerosis. Proceedings of 
the MS Forum, Rome: 21-23. 
 
O’Brien, B. (1987) Multiple Sclerosis.  Office of Health Economics: London. 
 
Poser, C.M., Paty, D.W., Schienberg, L., McDonald, W.I., Davis, J.A., Ebers, G.C., Johnson, 
K.P., Sibley, W.A., Sidderberg, D.H., and Tourtellette, W.W. (1983) New diagnostic 
criteria for multiple sclerosis: guidelines for research protocols.  Annals of Neurology, 13 
(3):227-231.  
 
Todd, C. (1995) Putting Multiple Sclerosis Under the Economic Spotlight Pharmacoresources, 9 
September, Adis International Limited. 
 
Whetten-Goldstein, K., Sloan, F., Conover, C., Viscusi, K., and Chesson, H. (1996) The 
economic burden of multiple sclerosis.  MS Management, 3(1):33-37. 
 
Wood, C. (1994) The cost of multiple sclerosis – A pharmacoeconomic model. Mineo University 
of Oxford: Oxford. 
 
 44
 45
Appendix 1: Clinical criteria for relapsing-remitting MS 
 
(Reference: Poser et al. 1983). 
 
Clinically Definite Multiple Sclerosis (CDMS). 
1. Two attacks and clinical evidence of two separate lesions. 
2. Two attacks, clinical evidence of one lesions and paraclinical evidence of another, 
separate lesion. 
 
Laboratory Supported Definite Multiple Sclerosis (LSDMS). 
The laboratory support consists of demonstration in CSF of IgG oligoclonal bands of increased 
CNS synthesis of IgG.  Oligoclonal bands must not be present in the patient’s serum, and the 
serum IgG level must be normal. 
1. One attack; either clinical or paraclinical evidence of one lesion; and CSF OB/IgG. 
2. One attack; clinical evidence of two separate lesions; and CSF OB/IgG. 
3. One attack; clinical evidence of one lesion and paraclinical evidence of another, separate 
lesion; and CSF OB/IgG.  
 
Clinical Probable Multiple Sclerosis (CPMS). 
1. Two attacks and clinical evidence of one lesion. 
2. One attack and clinical evidence of two separate lesions. 
3. One attack; clinical evidence of one lesion and paraclinical evidence of another, separate 
lesion. 
 
Laboratory Supported Probable Multiple Sclerosis (LSPMS). 
1. Two attacks and CSF OB/IgG. 
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Appendix 2: The Questionnaire 
 
Multiple Sclerosis Questionnaire 
 
 
MEDICAL SECTION 
 
 
 
1. In what year was your first symptom? ........................................................ 
 
 How certain are you about the date?  Very certain   
       Fairly certain   
       Unsure    
 
2. Who diagnosed you? ....................................................................................... 
 
 
3. What was the year you were diagnosed? .......................................................... 
 
4. What is your date of birth? .............................................................................. 
 
5. What were your main symptoms before you were diagnosed? 
 
       Fatigue  ?   
       Vision   ? 
       Mobility  ? 
       Sensory  ? 
       Bladder  ? 
       Bowel   ? 
       Pain   ? 
       Memory  ?   
       Depression  ? 
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       Weakness  ?   
       Spasticity  ?   
       Balance  ? 
       Co-ordination  ? 
       Tremor  ? 
       Other   ?   
6. What are your main symptoms now? 
 
       Fatigue  ? 
       Vision   ? 
       Mobility  ?  
       Sensory  ? 
       Bladder  ? 
       Bowel   ? 
       Pain   ? 
       Memory  ? 
       Depression  ? 
       Weakness  ? 
       Spasticity  ? 
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       Balance  ? 
        Co-ordination  ? 
       Tremory  ? 
       Other   ? 
 
7(a). How many attacks do you think you had in: 
 
       1996 
       1997     
       1998  
 
7(b). How accurate do you think that is? 
 
       Very accurate 
       Fairly accurate 
       A guess 
8. Are you having an attack at present? 
 
  Yes   No  
 
 If NO go to Question 11 
 
 
9. Are you having treatment for this attack? 
 
 
  Yes   No  
 
 
10. List treatments.    Methylprednisolone 
       Prednisone 
       Other 
 
11(a). Do you usually receive some medically prescribed treatment for your attacks? 
 
  Yes   No  
 
 If NO go to Question 12 
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11(b). List treatments.    Methylprednisolone 
       Prednisone 
       Other 
 
12a. How many attacks have you had treated in the last three years? 
 
  One  Two  Three  Four plus  
 
12b      Were you treated with methlyprednisolone each time? 
 
           Yes                    No 
 
13. How often in the last six months have you seen your neurologist or 
 the hospital registrar? 
 
  Number of times  
 
 
14. Were you seen privately or in the public health system? 
 
  Private     Public   Both   
 
 
15. Who is your current neurologist? ............................................................ 
 
16(a). In the last six months, how often have you seen your G.P. for M.S.  
 related problems? 
 
  Nil  Once  2-3  4-5  6 plus   
 
16(b). Please tell me what for: .......................................................................... 
 ............................................................................................................... 
 ............................................................................................................... 
 
 
17. Have you seen any other health professional in the last six months 
 because of your M.S.? 
 
  Yes   No  
 
 
 If NO go to Question 19 
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18. Please tell me who you have seen.     
          Number of times 
  Specialist (e.g. urologist, ophthalmologist)   ______________ 
  Physiotherapist      ______________ 
  Occupational Therapist     ______________ 
  Speech Therapist      ______________ 
  G.P. Nurse       ______________
  Domiciliary Nurse      ______________ 
  Needs Assessor      ______________ 
  Continence Nurse      ______________ 
  Podiatrist       ______________ 
  Optometrist       ______________ 
  Splint Department Nurse     ______________ 
  M.S. Society staff      ______________ 
  Other hospital staff (e.g. spinal unit)    ______________ 
  Hospital dental staff      ______________ 
  Other        ______________ 
 
19(a). Are you currently taking any other medication prescribed by your G.P., your 
 Neurologist, or other medical specialist, for problems associated with your M.S. ? 
 
  Yes   No  
 
 If NO got to Question 20 
 
19(b). Please tell me what medications you are taking from these people. 
 
     ................................................................. 
 
     ................................................................. 
 
     .................................................................. 
 
     .................................................................. 
 
     .................................................................. 
 
20. Including at the moment, in the last six months, have you consulted or  
 received treatment from an alternative therapist for M.S. related problems? 
 
  Yes   No  
 
 If NO got to Question 22 
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21. Please tell me what treatments you received. 
 
     ................................................................. 
 
     ................................................................. 
 
     .................................................................. 
 
     .................................................................. 
 
      
22. Are you taking anything else based on your own decision, e.g. from the chemist, herbal 
shop etc. for your M.S.? 
 
  Yes   No  
 
 If NO go to Question 23 
 If YES list:   .................................................................. 
 
     .................................................................. 
 
     .................................................................. 
 
 
23. Have you received Intravenous Methylprednisolone in the last six months? 
 
  Yes   No   
 
 If NO go to Question 26. 
 
 
24. Were you an: 
 
  In patient?  Outpatient?  Day patient?  
 
 
25. Where were you treated? Name of facility ....................................................... 
 
 
26. In the last six months, how many other times have you been at a hospital for your 
 M.S. or M.S. related problems (e.g. bladder) either as an in patient, day patient, or 
 outpatient?  (Circle number) 
 
 Inpatient 1 2 3 4 5 6 plus 
 Day patient 1 2 3 4 5 6 plus 
 Outpatient 1 2 3 4 5 6 plus 
 
 Total   
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PERSONAL CARE SECTION 
 
 
1(a). Have you been, in the last six months, into some kind of alternative living care 
because your M.S.? 
 
  Yes ?   No ?  
  
 If NO go to Question 2 
 
1(b). Please tell me where and for how many days. 
 
 ……………………………………………... 
 
2. Have you had a medical assessment at P.M.H. or Burwood Hospital in the last 
six months because of your M.S.? 
 
  Yes ?   No ? 
 
If NO go to Question 4 
 
3. How many days did this take? 
  
 Up to 3  ?      4 – 7  ?      8 – 10  ?      11 – 14   ?       more   ?  
 
4. Have you had a needs assessment in your5 home in the last six months because 
of your M.S.? 
 
  Yes ?   No ?  
 
5. Have you used any of the following services in the last six months because of 
your M.S.? 
 
  Yes ?   No ?  
 
 If YES then itemise.  If NO go to Question 7. 
 
 Continence clinic  ?  Meals on Wheels ?  
 District Nurse   ?  Child Care  ? 
 Home Care 2000  ?  Needs Assessment ? 
 Nurse Maude home support ?  Lifelink  ? 
 Personal Care   ?  C.C.S Home Health  ? 
 Domestic support  ?  Equipment  ? 
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 Dom. Services (O.T., P.T.) ?  Patient appliances ? 
 New Equipment (last Mth) ?  Private home help ?  
 Other    ?  Orthotics  ?  
 Carer Support   ? 
  
  List of all equipment: 
..………………………………..…………………………………………………
…………………………………………………………………………………… 
 
6. What are you using at the moment? 
 
Continence Clinic  ?  Meals on Wheels ? 
District Nurse   ?  Child Care  ? 
Home Care 2000  ?  Needs Assessment ? 
Nurse Maude   ?  Lifelink  ? 
Personal Care   ?  C.C.S. Home Health ? 
Domestic Support  ?  Equipment  ? 
Dom. Services (O.T.,P.T.) ?  Patient appliances ? 
New Equipment (last Mth) ?  Private Home Help ? 
Other    ?  Orthotics  ? 
Carer Support   ? 
 
List all equipment  
………………………………….………………………………………………
…………………………………………………………………………………. 
 
7. Do you live:  Alone    ? 
    With a spouse/partner  ? 
    Children under 18  ? 
    Adult children   ? 
    Parent/s   ? 
    Other Relative   ? 
    Other, e.g. flatmate, friend ? 
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    Hospital/Rest home  ? 
 
 
8(a). Do any of these people provide you with any assistance because of your MS? 
 
  Yes ?   No ? 
  
If NO finish  
 
8(b). Who  …………………………………………… 
 
8(c). How do they help you?  List tasks: ………………………… 
          ………………………… 
          …………………………  
 
8(d). Does anyone else provide you with help? e.g. relative, friend etc. 
 
  Yes ?   No ? 
 
 
 
 
INCOME/EMPLOYMENT SECTION 
 
 
1(a) Are you currently in paid employment? 
 
  Yes   No  
 
 If NO go to Question 8.  If YES complete question 
 
 
1(b). Full time  Number of hours: .................... 
 Part time  Number of hours: .................... 
 Self employed  Number of hours: .................... 
 
 
2. Are you able to do your paid work from home? 
 
  Yes   No  
 
 
3. Approximately how many days have you lost from paid work in the last 
 six months because of M.S. related problems? 
        ............................. 
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4(a). Have your work hours ever been reduced because of your M.S. related problems? 
 
  Yes   No  
 
 If NO go to Question 7 
 
4(b). If YES, in what year did your first reduce your hours? .............................. 
 
 
5. Have your work hours returned to their usual level? 
 
  Yes   No  
 
 
6. If NO, by how many hours have you reduced your paid work per week since you  
 have had M.S.? 
 
  Number of hours: ................... Hourly rate:  $..................... (if known) 
 
 
7. Have you changed, at any time, the type of paid work you do, because of your M.S.? 
 
  Yes   No  
 
 If YES go to Question 11                   If NO, list changes, go to Question 11 
 
............................................................................................................................ 
 .....................................................................................current position year started:  
8. Why are you not in paid work at present? ............................................................ 
 
9. How long is it since you were in paid employment? 
 
  Weeks .................... Months ....................  Years .................... 
 
10. What was you annual income when you left paid employment? .................... 
 
 
 
11. For people living with a partner.  Has your partner left paid work to assist you? 
 
  Yes   No  
 
 
11(a)    Ever left work to assist you? 
 
             Yes    No 
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PARTNER 
12. This question to partners.  Have you reduced your hours of paid employment 
 because of multiple sclerosis? 
 
  Yes   No  
 
PARTNER 
12(a)   Have you increased your hours of work because of MS? 
 
  Yes    No 
 
13. Are you able to remember what your maximum annual income was before you
 stopped paid employment, or reduced your hours because of your M.S. 
 
  Amount: .........................  person with M.S.  Year: ..................... 
  Amount: .........................  spouse/partner/carer Year:   ................... 
 
14. How much is your annual income now? 
 
  Amount: .........................  person with M.S. 
  Amount: .........................  spouse/partner/carer  
 
 
15(a). Are you receiving any means-tested benefits? 
 (Explain if necessary, e.g. sickness, invalids) 
 
  Yes   No  
 
 If NO go to Question 16 
 
15(b). Which benefit/s are you receiving? (Tick all appropriate)  AMOUNTS 
 
 Sickness Benefit      …………………..
  Invalid’s Benefit      …………………..
  National Superannuation     …………………..
  Family Support      …………………..
  Widows       …………………..
  Accommodation Allowance     …………………..
 Domestic Purposes Benefit     …………….……
 Unemployment and Training     ………………….
 Independent Youth Benefit     ………………….
 Job Search Allowance      ………………….
  Training Incentive Allowance    ………………….
 Special Benefit      ………………….
  Emergency Benefit      ………………….
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  Disability Allowance      ………………….
  High Use Card      ………………….
  Community Services Card     …………………. 
 Other        ………………….
     
15(c). Which of the benefits that you receive are because you have M.S.?  ........................... 
 ..........................................................................................................................……….. 
 
16(a). In the last five years have you had a grant from lottery (not for a car) 
 or any other private trust or source (e.g. Hyman Marks Trust)? 
 
  Yes   No  
 
 If NO go to Question 17. 
 
16(b). What was the grant for? .......................................................................................... 
 
16(c). How much was the grant? ........................................................................................ 
 
17(a). Have you received any support form ACC due to injury related to 
 your M.S (e.g. a fall, burn)? 
 
 
  Yes   No  
 
 If NO go to Finance Section. 
 
 
17(b). If YES please tell me what support you received (e.g. home help, personal care 
 hospitalisation, income). 
 
  List support received: ................................................................................ 
 
     ................................................................................ 
 
     ................................................................................. 
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FINANCIAL SECTION 
 
All costs recorded relate directly to multiple sclerosis costs only 
 
1. In the last five years have you paid for any alterations to your home? 
 
  Yes   No  Amount: ..................  Year: ................... 
 
1(a)   Have you had any home alterations paid for by the hospital system in the last two years? 
  Yes     No   Amount……………… Year………….. 
 
2. In the last five years have you sold anything to assist your finances 
 because of your M.S.?  (e.g. house, car, land) 
 
  Yes   No  
 
3. What? ....................................................... Amount: ..................  Year: ................... 
 
 
4. In the last five years have you moved into cheaper accommodation 
 because of your M.S.? 
 
  Yes   No  Year: ................... 
 
 
5. In the last five years have you bought a more expensive house to 
 accommodate your M.S.? 
 
  Yes   No  Year: ................... 
 
 
6. In the last five years have you paid for any of the following additional 
 services over the last 12 months because of your M.S.? 
 
  Gardener/lawn cutting   ............. p.w. 
  Home help (private)    ............. p.w. 
  Meals service     ............. p.w. 
  Child care     ............. p.w. 
  Personal help (e.g. showering)  ............. p.w. 
  Podiatrist (private)     ............. p.w. 
  Shopping     ............. p.w. 
  Other, list: (e.g. hairdresser at home) 
    ............................................  ............. p.w. 
    ............................................  ............. p.w. 
    ............................................  ............. p.w. 
      TOTAL  ............. p.w. 
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7. Do you receive any informal financial help from anyone, e.g. family members? 
 
  Yes   No  Amount: .................. p.w./month 
 
  8. Have you paid for any other items to assist you (e.g. commode, 
 new bed, garage door opener, continence supplies) in the last two years? 
 
  Yes   No  
 
 If NO go to Question 10 
 
  9. Please tell me what they were: 
 
  List    Cost        Date bought 
 ............................................ ................................ ............................. 
 ............................................ ................................ ............................. 
 ............................................ ................................ ............................. 
 
10(a). Have you spent any money on maintaining equipment to help your M.S. 
 in the last two years? 
 
  Yes   No   
 
10(b). Please state the item/s ............................................ amount ........................ 
    ............................................. amount ......................... 
    ............................................. amount ......................... 
 
 
TRANSPORT SECTION 
 
1. Do you drive? 
 
  Yes   No  
 
 If YES go to Question 2 
 If NO go to Question 3 
 
 
2. Have you upgraded your car in the last five years only because of your M.S.? 
 (e.g. automatic, power steer, etc.) 
 
  Yes   No  
 
 
3.       Have you had a car suspensory loan in the last five years? 
 
  Yes   No  Amount: ..................  Year: ................... 
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4. Have you ever had one? 
 
  Yes   No  Amount: ..................  Year: ................... 
 
5. Do you still have that car? 
 
  Yes   No  
 
 If NO explain ...................................................................................................... 
 
6. Have you had hand controls fitted or other alternations done? 
 
  Yes   No  Amount: ..................  Year: ................... 
 
7. Did you pay for these? 
 
  Yes   No  Amount: ..................  Year: ................... 
 
 or DID NZISS/SRHA pay? 
 
  Yes   No  Amount: ..................  Year: ................... 
 
8. Do you have a NZISS/SRHA car loan now? 
 
  Yes   No  Amount: ..................  Year: ................... 
 
9. Have you had a lottery grant for a car? 
 
  Yes   No  Amount: ..................  Year: ................... 
 
10. Have you had a driving assessment at Christchurch Hospital? 
 
  Yes   No  Year: ................... 
 
What forms of transport do you use? 
 
  Family or own car    
  Car driven by other person    
  Taxi/maxi taxi      
  Maxi taxi only     
  Bus      
  Other      
 
 Total weekly transport costs ............................................................................... 
 
N.B. Questions relating to M.S. transport costs will be itemised in relation to G.P. visits, 
hospital visits/treatments, etc. as M.S. related transport costs. 
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